<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Lidocaine (topical): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Lidocaine (topical): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Lidocaine (topical): Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9478" href="/d/html/9478.html" rel="external">see "Lidocaine (topical): Drug information"</a> and <a class="drug drug_patient" data-topicid="12242" href="/d/html/12242.html" rel="external">see "Lidocaine (topical): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F26714119"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Life-threatening and fatal events in infants and young children:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Postmarketing cases of seizures, cardiopulmonary arrest, and death in patients under the age of 3 years have been reported with use of lidocaine 2% viscous solution when it was not administered in strict adherence to the dosing and administration recommendations. In the setting of teething pain, lidocaine 2% viscous solution should generally not be used. For other conditions, the use of the product in patients less than 3 years should be limited to those situations where safer alternatives are not available or have been tried but failed. </p>
<p style="text-indent:-2em;margin-left:2em;">To decrease the risk of serious adverse events with use of lidocaine 2% viscous solution, instruct caregivers to strictly adhere to the prescribed dose and frequency of administration and store the prescription bottle safely out of reach of children.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F8768584"><span class="drugH1">Brand Names: US</span>
<ul>
<li>7T Lido;</li>
<li>Alocane Emergency Burn Max Str [OTC];</li>
<li>AneCream [OTC];</li>
<li>AneCream5 [OTC];</li>
<li>Asperflex Lidocaine [OTC];</li>
<li>Asperflex Max St [OTC];</li>
<li>Asperflex Pain Relieving [OTC];</li>
<li>Astero;</li>
<li>Blue Tube/ Aloe [OTC] [DSC];</li>
<li>DermacinRx Lidogel;</li>
<li>Eha;</li>
<li>First Care Pain Relief [OTC];</li>
<li>Gen7T;</li>
<li>Glydo;</li>
<li>GoodSense Burn Relief [OTC];</li>
<li>HealthWise Pain Relief [OTC];</li>
<li>LDO Plus;</li>
<li>LevigoSP [OTC];</li>
<li>Lido King [OTC];</li>
<li>Lido-Sorb;</li>
<li>Lidocaine Max St 24 Hours [OTC];</li>
<li>Lidocaine Pain Relief Max St [OTC];</li>
<li>Lidocaine Pain Relief [OTC];</li>
<li>Lidocaine Plus [OTC];</li>
<li>Lidocan;</li>
<li>Lidocan II [DSC];</li>
<li>Lidocan III;</li>
<li>Lidocanna [OTC];</li>
<li>Lidocore [OTC];</li>
<li>Lidoderm;</li>
<li>LidoDose Pediatric Bulk Pack [OTC];</li>
<li>LidoDose [OTC];</li>
<li>LidoFore Flexipatch [OTC] [DSC];</li>
<li>Lidogel [OTC] [DSC];</li>
<li>LidoHeal-90 [OTC] [DSC];</li>
<li>LidoLite;</li>
<li>Lidopac [DSC];</li>
<li>Lidopin;</li>
<li>LidoPure Patch;</li>
<li>Lidorex;</li>
<li>LidoRx;</li>
<li>Lidosol;</li>
<li>Lidosol-50;</li>
<li>Lidotral;</li>
<li>Lidotran;</li>
<li>Lidotrex (Aloe Vera) [DSC];</li>
<li>Lidovex [DSC];</li>
<li>Lidovix L;</li>
<li>Lidozion [DSC];</li>
<li>Lipocaine 5 [OTC];</li>
<li>LMX 4 Plus [OTC];</li>
<li>LMX 4 [OTC];</li>
<li>LMX 5 [OTC];</li>
<li>Lubricaine [OTC];</li>
<li>Lydexa;</li>
<li>Medi-First Burn Spray [OTC];</li>
<li>Moxicaine [DSC];</li>
<li>NeuroMed7 [OTC] [DSC];</li>
<li>NumbCream [OTC];</li>
<li>Pain Relief Maximum Strength [OTC];</li>
<li>Pain Relieving [OTC] [DSC];</li>
<li>Pharmacist Choice Pain Relief [OTC];</li>
<li>Predator [OTC] [DSC];</li>
<li>Premium Lidocaine;</li>
<li>Proxivol;</li>
<li>RadiaGuard Advanced [OTC];</li>
<li>Re-Lieved Maximum Strength [OTC];</li>
<li>RectaSmoothe [OTC];</li>
<li>RectiCare [OTC];</li>
<li>RectoProtect [OTC];</li>
<li>Salonpas Pain Relieving [OTC];</li>
<li>Sun Burnt Plus [OTC];</li>
<li>TheraCare Pain Relief [OTC];</li>
<li>Topicaine 5 [OTC];</li>
<li>Topicaine [OTC];</li>
<li>Venipuncture Px1 Phlebotomy;</li>
<li>XeroBurn [OTC];</li>
<li>Xolido XP [OTC] [DSC];</li>
<li>Xolido [OTC] [DSC];</li>
<li>Xyliderm;</li>
<li>ZiloVal [DSC];</li>
<li>Zingo;</li>
<li>Zionodil;</li>
<li>Zionodil 100;</li>
<li>ZTlido;</li>
<li>Zylotrol-L [OTC] [DSC]</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52869230"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Cathejell;</li>
<li>Jelido;</li>
<li>Lidodan;</li>
<li>Lidodan Endotracheal;</li>
<li>Xylocaine;</li>
<li>Xylocaine Spray</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F10529567"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Analgesic, Topical</span>;</li>
<li>
<span class="list-set-name">Local Anesthetic, Topical</span>;</li>
<li>
<span class="list-set-name">Local Anesthetic, Transdermal</span></li></ul></div>
<div class="block don drugH1Div" id="F53462662"><span class="drugH1">Dosing: Neonatal</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> Smaller areas of treatment are recommended in younger or smaller patients (&lt;12 months or &lt;10 kg) or those with impaired elimination (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23109683']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23109683'])">Ref</a></span>); use lowest effective dose.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c81c702e-1b12-4f44-8682-73da993d6e75">Circumcision; anesthetic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Circumcision; anesthetic:</b> Topical: Cream: LMX 4 (lidocaine 4%): Full-term neonates: Apply 2 <b>g</b> of cream to foreskin and penis; occlude with plastic wrap; leave on for 20 to 30 minutes prior to circumcision (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.2','lexi-content-ref-16041631']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.2','lexi-content-ref-16041631'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F8768791"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> Smaller areas of treatment are recommended in younger or smaller patients (&lt;12 months or &lt;10 kg) or those with impaired elimination (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23109683']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23109683'])">Ref</a></span>); use lowest effective dose.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="eb479ed7-37f7-495a-84af-a27b520b54df">Anesthetic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anesthetic:</b> Topical: Dose varies with age, weight, and physical condition.</p>
<p style="text-indent:-2em;margin-left:4em;">Cream:</p>
<p style="text-indent:-2em;margin-left:6em;">Lidovex (lidocaine 3.75%), Lidocaine 4.12%: Infants, Children, and Adolescents: Apply a thin film to affected area 2 to 3 times daily as needed; maximum dose: 4.5 mg/kg/dose; not to exceed 300 mg/dose</p>
<p style="text-indent:-2em;margin-left:6em;">LMX 4 (lidocaine 4%): Children &gt;2 years and Adolescents: Apply a thin film to affected area up to 3 to 4 times daily as needed; maximum dose: 4.5 mg/kg/dose; not to exceed 300 mg/dose</p>
<p style="text-indent:-2em;margin-left:4em;">Gel: Children ≥2 years and Adolescents: Apply to affected area up to 3 to 4 times daily as needed; maximum dose: 4.5 mg/kg/dose; not to exceed 300 mg/dose</p>
<p style="text-indent:-2em;margin-left:4em;">Jelly: Children and Adolescents: Dose varies with age and weight; maximum dose: 4.5 mg/kg/dose; not to exceed 600 mg in a 12-hour period</p>
<p style="text-indent:-2em;margin-left:4em;">Lotion: Children and Adolescents: Apply to affected area up to 2 to 3 times daily as needed; maximum dose: 4.5 mg/kg/dose; not to exceed 300 mg/dose</p>
<p style="text-indent:-2em;margin-left:4em;">Ointment: Children and Adolescents: Apply to affected area; maximum dose: 4.5 mg/kg/dose; not to exceed 300 mg/dose</p>
<p style="text-indent:-2em;margin-left:4em;">Patch: OTC 4%: Children ≥12 years and Adolescents: Apply patch to painful area. Patch may remain in place for up to 12 hours. No more than 1 patch should be used in a 24-hour period.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="118e6d95-3b78-4297-8b1c-9f4ead3aecfe">Minor dermal procedures; anesthetic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Minor dermal procedures (eg, peripheral IV cannulation, venipuncture, lumbar puncture, abscess drainage, joint aspiration); anesthetic:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Intradermal injection: Zingo: Venipuncture or peripheral IV catheter insertion: Children ≥3 years and Adolescents: Apply one intradermal lidocaine (0.5 mg) device to the site planned for venipuncture, administer 1 to 3 minutes prior to the IV needle insertion; perform procedure within 10 minutes of application</p>
<p style="text-indent:-2em;margin-left:4em;">Topical: Cream LMX 4 (lidocaine 4%):</p>
<p style="text-indent:-2em;margin-left:6em;">Infants and Children &lt;4 years: Apply 1 <b>g</b> of cream to site 30 minutes prior to procedure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23109683','lexi-content-ref-15967972']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23109683','lexi-content-ref-15967972'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥4 years and Adolescents ≤17 years: Apply 1 to 2.5 <b>g</b> of cream to site 30 minutes prior to procedure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12042548','lexi-content-ref-23109683','lexi-content-ref-15601345','lexi-content-ref-14993579','lexi-content-ref-15967972']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12042548','lexi-content-ref-23109683','lexi-content-ref-15601345','lexi-content-ref-14993579','lexi-content-ref-15967972'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> For peripheral IV cannulation, some have recommended application to 6.25 cm<sup>2</sup> of skin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22243434']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22243434'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7f21f5bf-27d3-4762-9a58-c1e9887ad3e5">Oral inflammation or irritation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral inflammation or irritation:</b> Topical: <b>Note:</b> Not approved for relief of teething pain and discomfort in infants and children; serious adverse (toxic) effects, including fatalities, have been reported; AAP, AAPD, and ISMP strongly discourage use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.1','lexi-content-ref-AAPD.1','lexi-content-ref-ISMP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.1','lexi-content-ref-AAPD.1','lexi-content-ref-ISMP.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Oral solution (2% viscous): Dose should be adjusted according to patient's age, weight, and physical condition:</p>
<p style="text-indent:-2em;margin-left:6em;">Infants and Children &lt;3 years: 24 mg/dose (1.2 mL) applied to area with a cotton-tipped applicator no more frequently than every 3 hours; maximum dose: 4 doses per 12-hour period; should not be swallowed</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥3 years and Adolescents: Do not exceed 4.5 mg/kg/dose; maximum dose: 300 mg/dose; swished in the mouth and spit out no more frequently than every 3 hours; maximum dose: 4 doses per 12-hour period</p>
<p style="text-indent:-2em;margin-left:4em;">Topical solution (4%): <b>Note:</b> For use on mucous membranes of the oral and nasal cavities and proximal portions of the digestive tract; use lowest effective dose. Children and Adolescents: Do not exceed 4.5 mg/kg/dose; maximum dose: 300 mg/dose; applied with cotton applicator, cotton pack, or via spray; should not be swallowed</p>
<p style="text-indent:-2em;margin-left:4em;">Topical endotracheal solution, metered-dose spray (10 mg/actuation) [Canadian product]: Children 2 to &lt;12 years: Topical: Dose varies with age, weight, and application site.</p>
<p style="text-indent:-2em;margin-left:6em;">Maximum dose:</p>
<p style="text-indent:-2em;margin-left:8em;">Laryngotracheal: 3 mg/kg/dose</p>
<p style="text-indent:-2em;margin-left:8em;">Nasal/oropharyngeal: 4 to 5 mg/kg/dose</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="13171fc9-38e2-4c56-9479-9a3a13748dfe">Rectal pain, itching</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Rectal pain, itching:</b> Topical:</p>
<p style="text-indent:-2em;margin-left:4em;">Cream: LMX 5 (lidocaine 5%): Children ≥12 years and Adolescents: Apply to affected area up to 6 times daily</p>
<p style="text-indent:-2em;margin-left:4em;">Gel: Topicaine (lidocaine 5%): Children ≥12 years and Adolescents: Apply to affected area up to 6 times daily</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0e777738-55fd-42c2-ba2f-a7e115f78b31">Skin irritation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Skin irritation:</b> Topical: Cream: LMX 4 (lidocaine 4%): Children ≥2 years and Adolescents: Apply up to 3 to 4 times daily to intact skin</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51117802"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. Use caution in patients with severe renal impairment; accumulation of active metabolites may occur with long-term treatment.</p></div>
<div class="block dohp drugH1Div" id="F51117803"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use caution in patients with severe hepatic disease.</p></div>
<div class="block doa drugH1Div" id="F8768792"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9478" href="/d/html/9478.html" rel="external">see "Lidocaine (topical): Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f4a77419-4151-4000-ae49-2910090aec84">Anesthesia, topical</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anesthesia, topical: </b>
<b>Note:</b> Not all available products may be represented in dosing; also refer to manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Cream:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Aspercreme: Pain: Apply a thin layer to affected area every 6 to 8 hours, not to exceed 3 applications in a 24-hour period.</p>
<p style="text-indent:-2em;margin-left:6em;">Blue Tube, LMX 4: Skin irritation: Apply up to 3 to 4 times daily to intact skin.</p>
<p style="text-indent:-2em;margin-left:6em;">Lidotran 3.88%, Lidocaine 4.12%, Lidovex 3.75%: Skin irritation: Apply a thin film to affected area 2 to 3 times daily as needed.</p>
<p style="text-indent:-2em;margin-left:6em;">Lipocaine 5, LMX 5: Relief of anorectal pain and itching: Apply to affected area up to 6 times daily.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Gel:</i> Usual dosage: Apply to affected area ≤4 times daily as needed (maximum dose: 4.5 mg/kg, not to exceed 300 mg).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Product-specific dosing:</i></p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Astero 4%;</i> Apply 1 to 4 pumps to affected area; each pump provides 0.25 mL (lidocaine 10 mg) and covers a 2 × 2 inch area. Maximum single application: 4 pumps (lidocaine 40 mg); maximum daily application: 12 pumps/day (lidocaine 120 mg/day).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>LidoRx 3%:</i> Apply 1 to 4 pumps to affected area 3 to 4 times daily; each pump provides 0.25 mL (lidocaine 7.5 mg) and covers a 2 × 2 inch area. Maximum single application: 4 pumps (lidocaine 30 mg); maximum daily application: 16 pumps/day (lidocaine 120 mg/day).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Topicaine 5%:</i> Apply to affected area up to 6 times daily.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Intradermal injection:</i> Apply one intradermal lidocaine (0.5 mg) device to the site planned for venipuncture, 1 to 3 minutes prior to needle insertion.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Jelly:</i> Maximum dose: 30 mL (600 mg) in any 12-hour period:</p>
<p style="text-indent:-2em;margin-left:6em;">Anesthesia of male urethra: 5 to 30 mL (100 to 600 mg).</p>
<p style="text-indent:-2em;margin-left:6em;">Anesthesia of female urethra: 3 to 5 mL (60 to 100 mg).</p>
<p style="text-indent:-2em;margin-left:6em;">Lubricant, endotracheal intubation (Glydo): Apply moderate amount to external surface of the endotracheal tube prior to insertion.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Lotion:</i> Apply a thin film to affected area 2 to 4 times daily; product-specific application frequency may vary; also refer to manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Ointment:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Intubation (5% ointment only): Apply 5 g of ointment (equivalent to lidocaine base 250 mg [~6 inches of ointment]) in a single application to the tube prior to intubation; maximum: 20 g of ointment/day (equivalent to lidocaine base 1,000 mg/day).</p>
<p style="text-indent:-2em;margin-left:6em;">Pain (eg, skin irritation, sunburn): Apply to affected area 3 to 4 times daily, not to exceed 5 g of ointment (equivalent to lidocaine base 250 mg) in a single application; maximum: 20 g of ointment/day (equivalent to lidocaine base 1,000 mg/day).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Oral topical solution (2% viscous):</i></p>
<p style="text-indent:-2em;margin-left:6em;">Anesthesia of the mouth: 15 mL swished in the mouth and spit out no more frequently than every 3 hours (maximum: 4.5 mg/kg [or 300 mg per dose]; 8 doses per 24-hour period).</p>
<p style="text-indent:-2em;margin-left:6em;">Anesthesia of the pharynx: 15 mL gargled no more frequently than every 3 hours (maximum: 4.5 mg/kg [or 300 mg per dose]; 8 doses per 24-hour period); may be swallowed.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Oral topical solution (4%): </i>
<b>Note: </b> For use in mucous membranes of oral and nasal cavities and proximal GI tract. Apply 1 to 5 mL (40 to 200 mg) to affected area (maximum dose: 4.5 mg/kg, not to exceed 300 mg per dose).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Oral topical endotracheal solution, metered-dose spray (10 mg/actuation) [Canadian product]: </i></p>
<p style="text-indent:-2em;margin-left:6em;">Nasal: 20 to 60 mg (maximum dose: 500 mg for procedure &lt;1 minute or 600 mg for procedure &gt;5 minutes).</p>
<p style="text-indent:-2em;margin-left:6em;">Oropharyngeal: 20 to 200 mg (maximum dose: 500 mg for procedure &lt;1 minute or 600 mg for procedure &gt;5 minutes).</p>
<p style="text-indent:-2em;margin-left:6em;">Respiratory tract: 50 to 400 mg (maximum dose: 400 mg for procedure &lt;1 minute or 600 mg for procedure &gt;5 minutes).</p>
<p style="text-indent:-2em;margin-left:6em;">Trachea, larynx, bronchi: 50 to 200 mg (maximum dose: 200 mg for procedure &lt;1 minute or 400 mg for procedure &gt;5 minutes).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Patch:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Pain (localized):</p>
<p style="text-indent:-2em;margin-left:8em;">3.5% products: Apply patch to painful area. Patch may remain in place for up to 12 hours in any 24-hour period. No more than 1 patch should be used in a 24-hour period.</p>
<p style="text-indent:-2em;margin-left:8em;">4% products: Apply patch to painful area. <b>Note:</b> The manufacturer’s recommendations for the number of patches that can be applied within a 24-hour period varies from 1 to 4 times daily and the duration of application varies from 8 to 24 hours; refer to the manufacturer’s labeling for product-specific recommendations.</p>
<p style="text-indent:-2em;margin-left:6em;">Postherpetic neuralgia (1.8% [ZTlido], 5% products): <b>Note:</b> One ZTlido 1.8% patch provides equivalent lidocaine exposure to one 5% patch: Apply patch to most painful area. Up to 3 patches may be applied in a single application. Patch(es) may remain in place for up to 12 hours in any 24-hour period.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Rectal suppository:</i>
<b>Note: </b>Lidocaine suppositories have been discontinued in the United States for &gt;1 year. Insert 1 suppository (50 mg) rectally; maximum of 4 suppositories in 24 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Topical solution (OTC 4% [products labeled for external use only]):</i> Apply thin layer to affected area every 6 to 8 hours; maximum of 3 applications in 24 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Topical spray (OTC 4% [products labeled for external use only]):</i> Apply to affected area up to 3 to 4 times daily; maximum of 4 applications in 24 hours.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990718"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block doha drugH1Div" id="F50988069"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling; use caution in patients with severe hepatic disease.</p></div>
<div class="block arsc drugH1Div" id="F58859445"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Reports of systemic <b>hypersensitivity reactions</b> following administration of topical lidocaine to mucous membranes, generally in the context of a procedure or nebulized lidocaine where systemic absorption is more likely, are rare (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3113575']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3113575'])">Ref</a></span>). These reactions may also result from excipients in lidocaine formulations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hotta.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hotta.2022'])">Ref</a></span>). Patients allergic to para-aminobenzoic acid (PABA) derivatives (eg, procaine, tetracaine, benzocaine) have not shown cross sensitivity to lidocaine.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Contact dermatitis</b>, a localized delayed Type IV hypersensitivity reaction, has also been reported with the use of lidocaine applied to the skin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10515104','lexi-content-ref-12622627','lexi-content-ref-29671489','lexi-content-ref-25380091','lexi-content-ref-9840272']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10515104','lexi-content-ref-12622627','lexi-content-ref-29671489','lexi-content-ref-25380091','lexi-content-ref-9840272'])">Ref</a></span>). These reactions may also result from excipients in lidocaine formulations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29790180']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29790180'])">Ref</a></span>). Type I hypersensitivity reactions are not of concern solely based on the presence of allergic contact dermatitis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25380091']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25380091'])">Ref</a></span>). Systemic toxicity has also been reported rarely with topical application (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16924052']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16924052'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Non–dose-related; immunologic. Signs and symptoms of immediate hypersensitivity reactions (eg, anaphylaxis) may be mediated by IgE or non-IgE mechanisms (ie, direct stimulation of mast cell and/or basophils, complement activation) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31757230']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31757230'])">Ref</a></span>). Allergic contact dermatitis is a delayed, T-lymphocyte–mediated reaction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33161140']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33161140'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Immediate hypersensitivity reactions: Rapid; usually occurs within 1 hour of administration; but may occur up to 6 hours after exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31757230']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31757230'])">Ref</a></span>). Allergic contact dermatitis generally occurs within 48 hours after application (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37283623']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37283623'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Cross-reactivity with other amide anesthetics, including bupivacaine, mepivacaine, and prilocaine, has been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8033557','lexi-content-ref-9840272']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8033557','lexi-content-ref-9840272'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Local anesthetic systemic toxicity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Topical lidocaine administration to mucous membranes, generally in the context of a procedure or nebulized lidocaine where systemic absorption is more likely, is associated with infrequent but potentially life-threatening local anesthetic systemic toxicity (LAST), a syndrome of CNS excitation and/or depression followed by cardiotoxicity, in some cases (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29525187','lexi-content-ref-35777259']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29525187','lexi-content-ref-35777259'])">Ref</a></span>). CNS effects include blurred vision, confusion, dizziness, drowsiness, respiratory depression, seizures, tremors, coma, and respiratory arrest (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22822998']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22822998'])">Ref</a></span>). Drowsiness may be an early sign of high lidocaine serum concentrations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31461049']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31461049'])">Ref</a></span>). Cardiovascular effects include bradycardia, hypotension, cardiovascular collapse, and cardiac arrest (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18280086','lexi-content-ref-28652958']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18280086','lexi-content-ref-28652958'])">Ref</a></span>). CNS effects typically precede cardiotoxicity. Symptom severity increases with increasing lidocaine serum concentrations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35777259']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35777259'])">Ref</a></span>). Symptoms of LAST may be reversible with prompt treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35777259','lexi-content-ref-29356773']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35777259','lexi-content-ref-29356773'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17175824','lexi-content-ref-30009240','lexi-content-ref-31932460']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17175824','lexi-content-ref-30009240','lexi-content-ref-31932460'])">Ref</a></span>); blockage of voltage-gated sodium channels in the CNS disrupts depolarization of inhibitory neurons, leading to neural excitation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35777259']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35777259'])">Ref</a></span>). With increasing lidocaine plasma concentrations, CNS depression occurs. Sodium channel blockade in myocardial tissue results in action potential inhibition, decreased contractility, conduction disturbance, and/or arrhythmia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36908108','lexi-content-ref-28652958','lexi-content-ref-35777259']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36908108','lexi-content-ref-28652958','lexi-content-ref-35777259'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Rapid; typically occurs within minutes of exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30009240']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30009240'])">Ref</a></span>). Severe symptoms may appear within hours of initial symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36162843']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36162843'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Lidocaine blood concentration &gt;5 mcg/mL</p>
<p style="text-indent:-2em;margin-left:6em;">• Application to mucous membranes in high doses (preceding airway instrumentation for awake intubation) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35777259']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35777259'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Intentional or unintentional overdose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29525187','lexi-content-ref-28652958','lexi-content-ref-30009240']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29525187','lexi-content-ref-28652958','lexi-content-ref-30009240'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Extremes of ages (&lt;16 or &gt;60 years of age) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29356773']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29356773'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Low muscle mass (neonates, infants, debilitated older patients) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29356773']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29356773'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29356773']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29356773'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Pregnancy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29356773']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29356773'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Chronic malnutrition (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29356773']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29356773'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Organ dysfunction (eg, cardiac, CNS, hepatic, kidney) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35777259','lexi-content-ref-29356773']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35777259','lexi-content-ref-29356773'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Acidosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35777259']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35777259'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Hypoxia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35777259']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35777259'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Methemoglobinemia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Topical lidocaine administration to mucous membranes, generally in the context of a procedure or nebulized lidocaine where systemic absorption is more likely, is rarely associated with <b>methemoglobinemia</b>, a serious and possibly life-threatening condition that is reversible with prompt treatment. Symptoms of methemoglobinemia include cyanosis (pale, gray, or blue skin), headache, fatigue, shortness of breath, and tachycardia. Severity of symptoms varies based on the level of methemoglobin in the blood (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34467556']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34467556'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Non–dose-related; idiosyncratic. Topical lidocaine exposure via mucous membrane(s) leads to acceleration of heme iron oxidation and conversion from the ferrous to ferric state, producing methemoglobin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34467556']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34467556'])">Ref</a></span>). Blood methemoglobin levels increase above the compensatory ability of the body, resulting in clinically significant methemoglobinemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20831930']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20831930'])">Ref</a></span>). Because methemoglobin transports and releases less oxygen into peripheral tissues than normal hemoglobin, hypoxia ensues.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Rapid; typically occurs within minutes to hours of exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29627919']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29627919'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Glucose-6-phosphate dehydrogenase (G6PD) deficiency</p>
<p style="text-indent:-2em;margin-left:6em;">• Congenital or idiopathic methemoglobinemia</p>
<p style="text-indent:-2em;margin-left:6em;">• Cardiac or pulmonary compromise (acute and/or chronic)</p>
<p style="text-indent:-2em;margin-left:6em;">• Age &lt;6 months</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent exposure to oxidizing agents or their metabolites (eg, dapsone, nitroglycerin, sulfamethoxazole) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34467556']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34467556'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent exposure to other local anesthetics (eg, benzocaine, prilocaine)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F8768636"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions are derived from product labeling unless otherwise specified. Adverse effects may vary with formulation and extent of systemic absorption; children may be at increased risk.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Bradycardia, circulatory shock, flushing, hypotension, shock</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Exfoliation of skin, papule of skin, skin blister, skin depigmentation, skin erosion, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dysgeusia, metallic taste, nausea, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Bruise</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema, hypersensitivity reaction, nonimmune anaphylaxis</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Application-site burning, application-site dermatitis, application-site edema, application-site erythema, application-site irritation, application-site pruritus, application-site purpuric or petechial reaction, application-site scaling, application-site vesicles, local skin discoloration, localized warm feeling</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Apprehension, asthenia, central nervous system depression, confusion, disorientation, dizziness, drowsiness, euphoria, excitement, headache, hyperesthesia, hypoesthesia, loss of consciousness, nervousness, numbness, paresthesia, seizure, sensation disorder (including sensation of cold), tremor, twitching</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Laryngospasm</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision, diplopia</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Tinnitus</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchospasm, dyspnea, respiratory depression</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Contact dermatitis (Montanez-Wiscovich 2018)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Methemoglobinemia (Gay 2016)</p></div>
<div class="block coi drugH1Div" id="F8768633"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to lidocaine or any component of the formulation; hypersensitivity to another local anesthetic of the amide type; traumatized mucosa, bacterial infection at the site of application (lotion, LidoRx, and Lidovex); tuberculous or fungal lesions of skin vaccinia, varicella and acute herpes simplex (3.88% and 4.12% cream).</p></div>
<div class="block war drugH1Div" id="F8768634"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Familial malignant hyperthermia: Many drugs used during the conduct of anesthesia may trigger familial malignant hyperthermia; not known whether amide-type local anesthetics trigger this reaction. However, standard protocol for management should be available. Early unexplained signs of tachycardia, tachypnea, labile blood pressure, and metabolic acidosis may precede temperature elevation. If familial malignant hyperthermia is confirmed, discontinue triggering agent and initiate appropriate therapy (eg, oxygen, dantrolene) and other supportive measures.</p>
<p style="text-indent:-2em;margin-left:4em;">• Local effects: Irritation, sensitivity and/or infection may occur at the site of application; discontinue use and institute appropriate therapy if local effects occur. Mild and transient application site reactions may occur during or immediately after treatment with patch; spontaneously resolves within a few minutes to hours; may include blisters, bruising, burning sensation, depigmentation, dermatitis, discoloration, edema, erythema, exfoliation, irritation, papules, petechial, pruritus, vesicles, or the area may be the locus of abnormal sensation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bleeding tendencies/platelet disorders: Intradermal injection: Use with caution; may have a higher risk of superficial dermal bleeding.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with severe shock or heart block.</p>
<p style="text-indent:-2em;margin-left:4em;">• Dermal integrity reduced: Application to broken or inflamed skin may lead to increased systemic absorption; use caution.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use caution in patients with severe hepatic disease due to diminished ability to metabolize systemically-absorbed lidocaine.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pseudocholinesterase deficiency: Use with caution; these patients have a greater risk of developing toxic plasma concentrations of lidocaine.</p>
<p style="text-indent:-2em;margin-left:4em;">• Sepsis/severely traumatized mucosa: Use with extreme caution in the presence of sepsis and/or severely traumatized mucosa due to an increased risk of rapid systemic absorption at application site.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Intradermal injection: Only use on intact skin and on skin locations where an adequate seal can be maintained. Do not use on body orifices, mucous membranes, around the eyes, or on areas with a compromised skin barrier.</p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Topical cream, liquid, lotion, gel, and ointment: Do not leave on large body areas for &gt;2 hours. Not for ophthalmic use. Some products are not recommended for use on mucous membranes; consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Topical oral solution/viscous: When used in mouth or throat, topical anesthesia may impair swallowing and increase aspiration risk. Avoid food for ≥60 minutes following oral or throat application. This is especially important in the pediatric population. Numbness may increase the danger of tongue/buccal biting trauma; ingesting food or chewing gum should be avoided while mouth or throat is anesthetized. Excessive doses or frequent application may result in high plasma levels and serious adverse effects; strictly adhere to dosing instructions. Use measuring devices to measure the correct volume, if applicable, to ensure accuracy of dose.</p>
<p style="text-indent:-2em;margin-left:4em;">• Topical patch: Apply only on intact skin. Do not use around or in the eyes. To avoid accidental ingestion by children, store and dispose of products out of the reach of children. Avoid exposing application site to external heat sources (eg, heating pad, electric blanket, heat lamp, hot tub).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Acutely ill patients: Use with caution; acutely ill patients should be given reduced doses commensurate with their age and physical status.</p>
<p style="text-indent:-2em;margin-left:4em;">• Elderly and debilitated patients: Use with caution; elderly and debilitated patients should be given reduced doses commensurate with their age and physical status.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Use with caution; children should be given reduced doses commensurate with their age and physical status.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Self-medication (OTC use): When used for self-medication, discontinue use and notify health care provider if condition worsens, symptoms persist for &gt;7 days, or symptoms clear up but reoccur within a few days.</p>
<p style="text-indent:-2em;margin-left:4em;">• Topical application: When topical anesthetics are used prior to cosmetic or medical procedures, the lowest amount of anesthetic necessary for pain relief should be applied. High systemic levels and toxic effects (eg, methemoglobinemia, irregular heartbeats, respiratory depression, seizures, death) have been reported in patients who (without supervision of a trained professional) have applied topical anesthetics in large amounts (or to large areas of the skin), left these products on for prolonged periods of time, or have used wraps/dressings to cover the skin following application.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878747"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">In infants and children, seizures (some fatal) have been reported following topical lidocaine ingestion at serum concentrations within the therapeutic range of 1 to 5 mcg/mL (Curtis 2009); others have reported toxic effects with excessive doses or frequent application of topical oral lidocaine solution that resulted in high plasma concentrations. Multiple cases of seizures, including fatalities, have occurred in pediatric patients using viscous lidocaine for oral discomfort (eg, teething pain, herpetic gingivostomatitis) (Curtis 2009; Giard 1983; Gonzalez del Rey 1994; Hess 1988; Mofenson 1983; Puczynski 1985; Rothstein 1982; Smith 1992). Lidocaine oral solution is not approved for treatment of teething pain or discomfort; off-label use is strongly discouraged and should be avoided. When used for oral irritation, the solution should not be swallowed, but should be applied topically with a cotton swab to individual lesions or the excess should be expectorated (swish and spit). Toxicology data suggests that in infants and children&lt;6 years, ingestion of as little as 5 mL of lidocaine may result in serious toxicity and emergency care should be sought (Curtis 2009). Additionally, the FDA recommends against using topical OTC medications for teething pain as some products may cause harm; the use of OTC topical anesthetics (eg, benzocaine) for teething pain is also discouraged by AAP, and The American Academy of Pediatric Dentistry (AAP 2011; AAPD 2012). The AAP recommends managing teething pain with a chilled (not frozen) teething ring or gently rubbing/massaging with the caregiver's finger.</p>
<p style="text-indent:0em;margin-top:2em;">Topical patches (both used and unused) may cause toxicities in children; used patches still contain large amounts of lidocaine; store and dispose patches out of the reach of children; efficacy of patches in pediatric patients has not been evaluated due to safety concerns.</p>
<p style="text-indent:0em;margin-top:2em;">Some dosage forms may contain propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Shehab 2009).</p></div>
<div class="block prod-avail drugH1Div" id="F57553496"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Lidocaine suppositories have been discontinued in the United States for &gt;1 year.</p></div>
<div class="block foc drugH1Div" id="F8768875"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Aerosol, External: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Alocane Emergency Burn Max Str: 4% (104 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">GoodSense Burn Relief: 0.5% (127 g) [contains disodium edta, methylparaben, propylene glycol, propylparaben, trolamine (triethanolamine)]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Cream, External: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">AneCream: 4% (5 g, 15 g, 30 g) [contains benzyl alcohol, polysorbate 80, propylene glycol, trolamine (triethanolamine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">AneCream5: 5% (15 g, 30 g) [contains benzyl alcohol, polysorbate 80, propylene glycol, trolamine (triethanolamine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Asperflex Lidocaine: 4% (5 g, 15 g, 30 g) [contains benzyl alcohol, polysorbate 80, propylene glycol, trolamine (triethanolamine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Blue Tube/ Aloe: 4% (30 g [DSC]) [contains benzyl alcohol, polysorbate 80, propylene glycol, trolamine (triethanolamine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lidotral: 3.88% (85 g) [contains cetearyl alcohol, methylparaben, propylene glycol, propylparaben]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lidotran: 3.88% (85 g) [contains cetearyl alcohol, methylparaben, propylene glycol, propylparaben]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lidovex: 3.75% (60 g [DSC]) [contains cetyl alcohol, propylene glycol, trolamine (triethanolamine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lipocaine 5: 5% (30 g, 113 g) [fragrance free, mineral oil free, no artificial color(s), paraben free; contains cetyl alcohol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">LMX 4: 4% (5 g, 15 g, 30 g) [contains benzyl alcohol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">LMX 5: 5% (15 g, 30 g) [contains benzyl alcohol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">NumbCream: 5% (38 g) [contains benzyl alcohol, polysorbate 80, propylene glycol, trolamine (triethanolamine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">RectaSmoothe: 5% (30 g) [contains cetyl alcohol, methylparaben, propylene glycol, propylparaben]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">RectiCare: 5% (15 g, 30 g) [contains benzyl alcohol, polysorbate 80, propylene glycol, trolamine (triethanolamine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">RectoProtect: 5% (30 g) [contains benzyl alcohol, polysorbate 80, propylene glycol, trolamine (triethanolamine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 4% (5 g, 15 g, 28 g, 28.35 g, 30 g, 120 g); 5% (14.17 g, 15 g, 28.35 g, 30 g)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Cream, External, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lidocaine Plus: 4% (120 g) [contains cetearyl alcohol, propylene glycol, trolamine (triethanolamine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lidopin: 3% (28 g, 85 g); 3.25% (28 g, 85 g) [contains cetyl alcohol, methylparaben, propylparaben]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lydexa: 4.12% (28.3 g, 85 g) [contains cetyl alcohol, methylparaben, propylene glycol, propylparaben]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">NeuroMed7: 4% (63 g [DSC]) [contains propylene glycol, trolamine (triethanolamine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Pain Relieving: 4% (15 g [DSC]) [contains cetearyl alcohol, disodium edta]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Predator: 4% (63 g [DSC]) [contains propylene glycol, trolamine (triethanolamine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Xolido: 2% (118 mL [DSC]) [contains methylisothiazolinone]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Xolido XP: 4% (118 mL [DSC]) [contains methylisothiazolinone]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 3% (28.3 g, 28.35 g, 85 g); 4% (30 g [DSC], 120 g); 4.12% (28.3 g, 85 g)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Gel, External: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">DermacinRx Lidogel: 2.8% (100 g) [contains methylparaben, propylene glycol, propylparaben]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lidogel: 2.8% (100 g [DSC]) [contains methylparaben, propylene glycol, propylparaben]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lidorex: 2.8% (100 g) [contains methylparaben, propylene glycol, propylparaben]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lubricaine: 4% (113 g); 5% (113 g) [estrogen free, fragrance free, no artificial color(s), no artificial flavor(s), paraben free, soy free, sugar free; contains benzyl alcohol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Topicaine: 4% (10 g, 30 g, 113 g) [contains benzyl alcohol, disodium edta]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Topicaine 5: 5% (10 g, 30 g, 113 g) [contains benzyl alcohol, disodium edta]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Gel, External, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Alocane Emergency Burn Max Str: 4% (75 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Astero: 4% (90 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">LDO Plus: 4% (30 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">LidoDose: 3% (1 mL) [contains isopropyl alcohol, trolamine (triethanolamine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">LidoDose Pediatric Bulk Pack: 3% (1 mL) [contains isopropyl alcohol, trolamine (triethanolamine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">LidoRx: 3% (10 mL, 30 mL, 90 mL) [contains isopropyl alcohol, trolamine (triethanolamine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lidotrex (Aloe Vera): 2% (28.33 g [DSC]) [contains trolamine (triethanolamine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Proxivol: 2% (28.33 g) [contains benzethonium chloride, trolamine (triethanolamine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Sun Burnt Plus: 4% (118 mL) [dye free, fragrance free, paraben free, phthalate free, sulfate free]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">7T Lido: 2% (85 g) [contains trolamine (triethanolamine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">XeroBurn: 2% (3.5 g) [contains methylparaben, propylene glycol, propylparaben, trolamine (triethanolamine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2% (5 mL [DSC], 30 mL [DSC])</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Jet-injector, Intradermal, as hydrochloride [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zingo: 0.5 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.5 mg (1 ea [DSC])</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Kit, External: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">AneCream: 4% [contains benzyl alcohol, polysorbate 80, propylene glycol, trolamine (triethanolamine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">LidoHeal-90: 4% [DSC] [contains cetostearyl alcohol, edetate (edta) disodium, methylparaben, propylene glycol, propylparaben]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">LidoLite: 5%</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lidopac: 5% [DSC] [contains polyethylene glycol (macrogol)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">LidoPure Patch: 5% [contains edetate (edta) disodium, methylparaben, propylene glycol, propylparaben]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lidosol: 5%</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lidosol-50: 5% [contains polyethylene glycol (macrogol)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lidovix L: 5% [contains polyethylene glycol (macrogol)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">LMX 4 Plus: 4% [contains benzyl alcohol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Moxicaine: 5% [DSC] [contains polyethylene glycol (macrogol)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Xyliderm: 5% [contains edetate (edta) disodium, methylparaben, propylene glycol, propylparaben]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">ZiloVal: 5% [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zylotrol-L: 4% [DSC] [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 4%</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Kit, External, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Venipuncture Px1 Phlebotomy: 2% [latex free; contains methylparaben, propylparaben]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Liquid, External, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">LevigoSP: 2.5% (150 mL) [paraben free; contains propylene glycol]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Lotion, External: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Gen7T: 3.5% (120 g) [contains edetate (edta) disodium, trolamine (triethanolamine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">RadiaGuard Advanced: 1% (113 g) [metallic free; contains cetyl alcohol, polysorbate 80, trolamine (triethanolamine)]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Lotion, External, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Eha: 4% (88 mL) [contains methylisothiazolinone]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lido-Sorb: 3% (177 mL) [contains cetyl alcohol, edetate (edta) disodium, methylparaben, propylparaben]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lidozion: 3% (177 mL [DSC]) [contains cetyl alcohol, edetate (edta) disodium, methylparaben, propylparaben]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zionodil: 3% (177 mL) [contains cetyl alcohol, edetate (edta) disodium, methylparaben, propylparaben]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zionodil 100: 3% (177 mL) [contains cetyl alcohol, propylene glycol, trolamine (triethanolamine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 3% (177 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Ointment, External: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Asperflex Lidocaine: 4% (100 g) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Premium Lidocaine: 5% (50 g)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 4% (50 g); 5% (30 g, 35.44 g, 50 g, 2500 g [DSC])</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Pad, External: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Alocane Emergency Burn Max Str: 4% (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Patch, External: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Asperflex Max St: 4% (6 ea) [odor free]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Asperflex Pain Relieving: 4% (5 ea) [fragrance free; contains polysorbate 80, propylene glycol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">First Care Pain Relief: 4% (5 ea) [odor free, paraben free]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">First Care Pain Relief: 4% (5 ea [DSC]) [odor free, paraben free; contains propylene glycol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Gen7T: 3.5% (10 ea, 15 ea) [contains propylene glycol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">HealthWise Pain Relief: 4% (15 ea) [odor free; contains methylparaben, polysorbate 80, propylene glycol, propylparaben]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lido King: 4% (5 ea) [contains edetate (edta) disodium, methylparaben, propylene glycol, propylparaben]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lidocaine Max St 24 Hours: 4% (15 ea) [odor free]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lidocaine Pain Relief: 4% (5 ea, 30 ea) [contains methylparaben, polysorbate 80, propylene glycol, propylparaben]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lidocaine Pain Relief Max St: 4% (1 ea, 5 ea) [odorless; contains edetate (edta) disodium, methylparaben, propylene glycol, propylparaben]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lidocan: 5% (1 ea, 30 ea) [contains disodium edta, methylparaben, propylene glycol, propylparaben]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lidocan II: 5% (1 ea [DSC], 30 ea [DSC]) [contains disodium edta, methylparaben, propylene glycol, propylparaben]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lidocan III: 5% (1 ea, 30 ea) [contains disodium edta, methylparaben, propylene glycol, propylparaben]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lidocanna: 4% (10 ea) [contains propyl hydroxybenzoate, propylene glycol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lidocore: 4% (10 ea) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lidoderm: 5% (1 ea, 30 ea) [contains disodium edta, methylparaben, propylene glycol, propylparaben]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lidoderm: 5% (1 ea, 30 ea) [contains edetate (edta) disodium, methylparaben, propylene glycol, propylparaben]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">LidoFore Flexipatch: 4% (5 ea [DSC]) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Pain Relief Maximum Strength: 4% (5 ea) [contains methylparaben, polysorbate 80, propylene glycol, propylparaben]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Pharmacist Choice Pain Relief: 4% (1 ea, 5 ea, 30 ea) [fragrance free; contains polysorbate 80, propylene glycol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Re-Lieved Maximum Strength: 4% (20 ea) [aluminum free, odor free]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Re-Lieved Maximum Strength: 4% (1 ea, 6 ea [DSC], 20 ea) [odor free]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Salonpas Pain Relieving: 4% (6 ea, 15 ea) [contains edetate (edta) disodium, methylparaben, propylene glycol, propylparaben]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Salonpas Pain Relieving: 4% (7 ea) [contains propylene glycol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">TheraCare Pain Relief: 4% (5 ea) [odor free; contains methylparaben, polysorbate 80, propylene glycol, propylparaben]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">ZTlido: 1.8% (1 ea, 30 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 3.5% (5 ea); 4% (10 ea, 15 ea); 5% (1 ea, 15 ea, 30 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Prefilled Syringe, External, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2% (20 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Prefilled Syringe, External, as hydrochloride [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Glydo: 2% (6 mL, 11 mL) [pvc free]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2% (5 mL, 10 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, External: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Medi-First Burn Spray: 2% (59.1 mL) [contains methylparaben, propylene glycol, propylparaben]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, External, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 4% (50 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Mouth/Throat, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2% (15 mL, 100 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Mouth/Throat, as hydrochloride [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 4% (4 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suppository, Rectal: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg (24 ea [DSC])</p></div>
<div class="block geq drugH1Div" id="F8768595"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F8768877"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Aerosol</b> (Alocane Emergency Burn Max Str External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4% (per mL): $0.13</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Cream</b> (AneCream External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4% (per gram): $1.28</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Cream</b> (AneCream5 External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5% (per gram): $1.60</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Cream</b> (Asperflex Lidocaine External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4% (per gram): $0.59</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Cream</b> (Lidocaine (Anorectal) External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5% (per gram): $0.52 - $1.97</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Cream</b> (Lidocaine External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4% (per gram): $0.74 - $2.07</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Cream</b> (Lidocaine HCl External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3% (per gram): $1.44 - $2.06</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4% (per gram): $3.70 - $3.75</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4.12% (per gram): $23.32</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Cream</b> (Lidotral External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3.88% (per gram): $17.63</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Cream</b> (Lidotran External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3.88% (per gram): $17.63</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Cream</b> (Lipocaine 5 External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5% (per gram): $0.72</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Cream</b> (LMX 4 External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4% (per gram): $1.68</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Cream</b> (LMX 5 External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5% (per gram): $2.42</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Cream</b> (Lydexa External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4.12% (per gram): $53.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Cream</b> (RectaSmoothe External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5% (per gram): $0.64</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Cream</b> (RectiCare External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5% (per gram): $1.23</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Cream</b> (RectoProtect External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5% (per gram): $0.48</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Gel</b> (7T Lido External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2% (per gram): $11.14</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Gel</b> (Alocane Emergency Burn Max Str External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4% (per mL): $0.18</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Gel</b> (Astero External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4% (per mL): $11.53</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Gel</b> (DermacinRx Lidogel External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.8% (per gram): $18.95</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Gel</b> (LDO Plus External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4% (per mL): $13.29</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Gel</b> (LidoDose External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3% (per mL): $3.50</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Gel</b> (LidoDose Pediatric Bulk Pack External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3% (per mL): $3.50</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Gel</b> (Lidorex External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.8% (per gram): $18.95</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Gel</b> (Lubricaine External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4% (per gram): $0.30</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5% (per gram): $0.30</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Gel</b> (Proxivol External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2% (per gram): $34.87</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Gel</b> (Sun Burnt Plus External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4% (per mL): $0.11</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Gel</b> (Topicaine 5 External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5% (per gram): $0.65</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Gel</b> (Topicaine External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4% (per gram): $1.05</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Gel</b> (XeroBurn External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2% (per gram): $0.04</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Jet-injector</b> (Zingo Intradermal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5 mg (per each): $365.30</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Kit</b> (AneCream External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4% (per each): $24.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Kit</b> (Lidocaine-Transparent Dressing External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4% (per each): $59.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Kit</b> (LidoPure Patch External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5% (per each): $23.44</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Kit</b> (LMX 4 Plus External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4% (per each): $48.07</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Kit</b> (Venipuncture Px1 Phlebotomy External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2% (per each): $981.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Kit</b> (Xyliderm External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5% (per each): $3,200.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Liquid</b> (Dologesic Pain Relief Roll-On External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4% (per mL): $0.13</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Lotion</b> (Lido-Sorb External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3% (per mL): $13.87</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Lotion</b> (Lidocaine HCl External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3% (per mL): $14.10</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Ointment</b> (Asperflex Lidocaine External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4% (per gram): $0.07</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Ointment</b> (Lidocaine External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4% (per gram): $6.00</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5% (per gram): $7.50 - $13.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Pads</b> (Alocane Emergency Burn Max Str External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4% (per each): $1.31</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Patch</b> (Asperflex Pain Relieving External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4% (per each): $1.22</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Patch</b> (First Care Pain Relief External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4% (per each): $46.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Patch</b> (Lido King External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4% (per each): $1.18</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Patch</b> (Lidocaine External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3.5% (per each): $46.20</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4% (per each): $46.00 - $49.50</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5% (per each): $3.42 - $49.80</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Patch</b> (Lidocan External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5% (per each): $64.17</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Patch</b> (Lidocan III External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5% (per each): $33.17</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Patch</b> (Lidoderm External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5% (per each): $31.81</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Patch</b> (Pharmacist Choice Pain Relief External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4% (per each): $1.50</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Patch</b> (Re-Lieved Maximum Strength External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4% (per each): $4.79</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Patch</b> (Salonpas Pain Relieving External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4% (per each): $1.35</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Patch</b> (ZTlido External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1.8% (per each): $14.16</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Prefilled Syringe</b> (Glydo External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2% (per mL): $1.19</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Prefilled Syringe</b> (Lidocaine HCl Urethral/Mucosal External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2% (per mL): $1.38 - $1.44</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Lidocaine HCl External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4% (per mL): $0.64 - $1.33</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Lidocaine HCl Mouth/Throat)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4% (per mL): $8.24</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Lidocaine Viscous HCl Mouth/Throat)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2% (per mL): $0.13 - $1.18</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Medi-First Burn Spray External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2% (per mL): $0.05</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52869231"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Gel, External, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Xylocaine: 2% (30 mL) [contains methylparaben, propylparaben]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Ointment, External: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lidodan: 5% (15 g, 30 g, 35 g)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Xylocaine: 5% (35 g) [contains polyethylene glycol (macrogol), propylene glycol]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Prefilled Syringe, External, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Jelido: 2% (6 mL, 11 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Xylocaine: 2% (10 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2% (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intratracheal, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Xylocaine Spray: 10 mg/actuation (50 mL) [contains alcohol, usp, menthol, polyethylene glycol (macrogol), saccharin]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mcg/actuation (30 mL, 60 mL)</p></div>
<div class="block admp drugH1Div" id="F52614370"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Topical:</p>
<p style="text-indent:-2em;margin-left:2em;">Cream, gel: Apply to affected area.</p>
<p style="text-indent:-2em;margin-left:4em;">LMX-4: Minor dermal procedure (peripheral IV cannulation, venipuncture): Infants and Children: Apply to skin at least 30 minutes before procedure; in most trials, occlusion of the application site was used (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15601345','lexi-content-ref-14993579','lexi-content-ref-15967972']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15601345','lexi-content-ref-14993579','lexi-content-ref-15967972'])">Ref</a></span>) while another trial showed that occlusion was not required (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12042548']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12042548'])">Ref</a></span>); however, occlusion of the site may be helpful in active infants and children to hold cream in place</p>
<p style="text-indent:-2em;margin-left:2em;">Intradermal injection device (eg, Zingo): Refer to manufacturer's labeling for administration technique. Apply intradermal lidocaine 1 to 3 minutes prior to needle insertion; perform procedure within 10 minutes following application. Application of <b>one</b> additional intradermal lidocaine at a new location is acceptable after a failed attempt at peripheral IV cannulation; multiple administrations of intradermal lidocaine at the same location are not recommended. Only use on intact skin and on skin locations where an adequate seal can be maintained. Do not use on body orifices, mucous membranes, around the eyes, or on areas with a compromised skin barrier. When removing the device from the pouch, be careful not to touch the purple outlet (open end) to avoid contamination; do not use if the device has been dropped or the pouch is damaged or torn.</p>
<p style="text-indent:-2em;margin-left:2em;">Ointment: Use of a sterile gauze is suggested for application to broken skin; apply to tube prior to intubation. In dentistry, apply to previously dried oral mucosa; subsequent removal of excess saliva with cotton rolls or saliva ejector minimizes dilution of ointment, permits maximum penetration, and minimizes possibility of swallowing the ointment. For use with the insertion of new dentures, apply to all denture surfaces contacting mucosa.</p>
<p style="text-indent:-2em;margin-left:2em;">Oral solution (2% viscous): Do not eat or chew gum for 60 minutes following use.</p>
<p style="text-indent:-2em;margin-left:4em;">Mouth irritation or inflammation: Have patient swish medication around mouth and then spit it out. In children &lt;3 years, apply small amount to affected area with cotton-tipped applicator (do not use to relieve teething pain).</p>
<p style="text-indent:-2em;margin-left:4em;">Pharyngeal anesthesia: Patient should gargle and may swallow medication. In children &lt;3 years, apply to affected area with cotton-tipped applicator.</p>
<p style="text-indent:-2em;margin-left:2em;">Rectal gel: Children ≥12 years and Adolescents: If possible, clean affected area with mild soap and water and blot dry prior to application.</p>
<p style="text-indent:-2em;margin-left:2em;">Topical patch:</p>
<p style="text-indent:-2em;margin-left:4em;">OTC 4%: Children ≥12 years and Adolescents: Remove protective film and apply to painful area. Avoid contact with eyes or mucous membranes. Wash hands after application. Avoid exposing application site to external heat sources (eg, heating pad, electric blanket, heat lamp, hot tub). Discard any used or unused patches by folding adhesive sides together and dispose of in trash away from children and pets.</p>
<p style="text-indent:-2em;margin-left:2em;">Topical oral endotracheal solution, metered-dose spray (10 mg/actuation) [Canadian product]: Attach nozzle and prime pump by actuating 5 to 10 times prior to first use; actuate ~2 times (to remove air) when switching to a new nozzle. Product should be in upright position while spraying. Do not modify manufacturer supplied nozzle. Discard nozzle after use (do not reuse). Do not use on cuffs or endotracheal tubes made of plastic (may damage cuff).</p></div>
<div class="block adm drugH1Div" id="F8768819"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Topical:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Cream, gel, lotion: For external use only; avoid contact with eyes. Also refer to manufacturer's labeling for additional product-specific application instructions.</p>
<p style="text-indent:-2em;margin-left:4em;">Intradermal injection: Refer to manufacturer's labeling for administration technique. Apply intradermal lidocaine 1 to 3 minutes prior to needle insertion; perform procedure within 10 minutes following application. Application of <b>one</b> additional intradermal lidocaine at a new location is acceptable after a failed attempt at venous access; multiple administrations of intradermal lidocaine at the same location are not recommended. Only use on intact skin and on skin locations where an adequate seal can be maintained. Do not use on body orifices, mucous membranes, around the eyes, or on areas with a compromised skin barrier. When removing the device from the pouch, be careful not to touch the purple outlet (open end) to avoid contamination; do not use if the device has been dropped or if the pouch is damaged or torn.</p>
<p style="text-indent:-2em;margin-left:4em;">Jelly:</p>
<p style="text-indent:-2em;margin-left:6em;">Urethral anesthesia: Anesthesia occurs within several minutes (full anesthetic effect occurs in 5 to 10 minutes after installation).</p>
<p style="text-indent:-2em;margin-left:6em;">Lubricant for endotracheal intubation (Glydo): Avoid introducing jelly into lumen of the tube. Do not use to lubricate endotracheal stylets. Avoid use of endotracheal tubes with dried jelly on the external surface for lack of lubricating effect.</p>
<p style="text-indent:-2em;margin-left:4em;">Ointment: Use of a sterile gauze is suggested for application to broken skin; apply to tube prior to intubation. In dentistry, apply to previously dried oral mucosa; subsequent removal of excess saliva with cotton rolls or saliva ejector minimizes dilution of ointment, permits maximum penetration, and minimizes possibility of swallowing the ointment. For use with the insertion of new dentures, apply to all denture surfaces contacting mucosa. Also refer to manufacturer's labeling for additional product-specific application instructions.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral topical solution (2% viscous):</p>
<p style="text-indent:-2em;margin-left:6em;">Mouth irritation or inflammation: Have patient swish medication around mouth and then spit it out. Do not eat or chew gum for 60 minutes following use.</p>
<p style="text-indent:-2em;margin-left:6em;">Pharyngeal anesthesia: Patient should gargle and may swallow medication. Do not eat or chew gum for 60 minutes following use.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral topical endotracheal solution, metered-dose spray (10 mg/actuation) [Canadian product]: Attach nozzle and prime pump 5 to 10 times prior to first use; prime ~2 times (to remove air) when switching to a new nozzle. Product should be in upright position while spraying. Do not modify manufacturer supplied nozzle. Discard nozzle after use (do not reuse). Do not use on cuffs or endotracheal tubes made of plastic (may damage cuff).</p>
<p style="text-indent:-2em;margin-left:4em;">Patch: <b>Note:</b> In general, the following instructions are considered applicable to all transdermal products; also refer to manufacturer's labeling for additional product-specific application instructions.</p>
<p style="text-indent:-2em;margin-left:6em;">Apply to most painful area of skin immediately after removal from protective envelope. Do not apply to nonintact skin. Some products may be cut to appropriate size (refer to manufacturer's labeling for details). Clothing may be worn over application area. Remove immediately if irritation or a burning sensation occurs. Wash hands after application. Contact with water (eg, bathing, swimming, showering) recommendations vary by product; refer to manufacturer's labeling for details. Avoid exposing application site to external heat sources (eg, heating pad, electric blanket, heat lamp, hot tub). After removal from skin, fold used patch so the adhesive side sticks to itself and dispose of in trash away from children and pets.</p>
<p style="text-indent:-2em;margin-left:4em;">Spray: For external use only; avoid contact with eyes. Avoid large quantities of spray, particularly on raw or blistered areas. Shake well. When applying to the face, spray on palm or hand first, then gently apply to face.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Rectal:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Rectal suppository: Remove wrapper; insert suppository into the rectum.</p></div>
<div class="block sts drugH1Div" id="F12705682"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">All formulations: Store at room temperature; see product-specific labeling for any additional storage requirements. Store and dispose of products out of the reach of children and pets.</p></div>
<div class="block usep drugH1Div" id="F53570629"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">In general, local anesthetic for oral mucous membrane; laser/cosmetic surgeries; minor burns, cuts, and abrasions of the skin; specific uses will vary based on product formulation (FDA approved in adults; refer to product specific information regarding FDA approval in pediatric patients)</p>
<p style="text-indent:-2em;margin-left:2em;">Product-specific indications:</p>
<p style="text-indent:-2em;margin-left:4em;">Cream: Temporary relief of pain and itching due to minor cuts, scrapes, burns, sunburn, minor skin irritations, and insect bites (Lidocaine 4.12%: FDA approved in pediatric patients [age not specified] and adults; OTC product: LMX 4: FDA approved in ages ≥2 years and adults); relief of pruritus, pruritic eczemas, abrasions, minor burns, insect bites, pain, soreness, and discomfort due to pruritus ani, pruritus vulvae, hemorrhoids, anal fissures, and similar conditions of the skin and mucous membranes (Lidovex 3.75%: FDA approved in pediatric patients [age not specified] and adults); liposomal cream (LMX 4) has also been used as topical anesthetic for minor dermal procedures (eg, venipuncture, peripheral IV cannulation)</p>
<p style="text-indent:-2em;margin-left:4em;">Gel: Temporary relief of pain and itching due to minor cuts, scrapes, burns, sunburn, minor skin irritations, and insect bites (OTC product: Alocane 4% gel: FDA approved in ages ≥2 years); relief of pain at site of injury; relief of musculoskeletal pain and soreness; relief of pain from neuropathy, local medical procedures, injections, and vaccines; relief of pruritus, pruritic eczemas, abrasions, minor burns, insect bites, pain, soreness, and discomfort due to pruritus ani, pruritus vulvae, hemorrhoids, anal fissures, and similar conditions of the skin and mucous membranes (LiDORx 3%: FDA approved in pediatric patients [age not specified] and adults); relief of topical pain, postsurgical pain, and pain associated with closed (soft tissue and bony injuries caused by contusions, hematomas, crush injuries, and sprains/strains due to torsion, traction, compression, and/or blunt trauma) or open wounds (Astero 4% gel: FDA approved ≥2 years); soothing wound gel to promote healing (Lidotrex 2%: FDA approved in adults); temporary relief of minor pain (Tranzarel 4%: FDA approved in adults); temporary relief of pain and itching due to anorectal disorders (OTC product: Topicaine 5: FDA approved in ages ≥12 years and adults)</p>
<p style="text-indent:-2em;margin-left:4em;">Intradermal injection (Zingo): Topical local analgesia prior to peripheral intravenous (IV) cannulation (FDA approved in ages 3 through 18 years) and topical local analgesia prior to venipuncture (FDA approved in ages ≥3 years and adults)</p>
<p style="text-indent:-2em;margin-left:4em;">Jelly: Lubrication for endotracheal intubation (oral and nasal) (FDA approved in pediatric patients [age not specified] and adults); prevention and control of pain in procedures involving the male and female urethra (FDA approved in adults); for topical treatment of painful urethritis (FDA approved in adults)</p>
<p style="text-indent:-2em;margin-left:4em;">Lotion: Topical anesthetic and local analgesic (Lido-K 3%: FDA approved in pediatric patients [age not specified] and adults); temporary relief of pain and itching due to cuts, scrapes, and minor burns (Eha 4%: FDA approved in ages ≥2 years and adults); temporary relief of pruritus, pruritic eczemas, abrasions, minor burns, insect bites, pain, soreness, and discomfort due to pruritus ani, pruritus vulvae, hemorrhoids, anal fissures, and similar conditions of the skin and mucous membranes (Anastia 2.75%: FDA approved in pediatric patients [age not specified] and adults)</p>
<p style="text-indent:-2em;margin-left:4em;">Ointment: Local anesthetic for oral mucous membranes (FDA approved in pediatric patients [age not specified] and adults); temporary relief of pain due to abrasions, minor burns, and insect bites (FDA approved in pediatric patients [age not specified] and adults); lubricant for intubation (FDA approved in pediatric patients [age not specified] and adults)</p>
<p style="text-indent:-2em;margin-left:4em;">Topical patch: Relief of pain associated with postherpetic neuralgia (Lidoderm, Ztlido: FDA approved in adults); temporary relief of minor localized pain (OTC product: Aspercreme patch: FDA approved in ages ≥12 years and adults; LidoPatch: FDA approved in adults)</p>
<p style="text-indent:-2em;margin-left:4em;">Rectal (LMX 5): Temporary relief of pain and itching due to anorectal disorders (FDA approved in ages ≥12 years and adults)</p>
<p style="text-indent:-2em;margin-left:4em;">Oral topical solution (2% viscous): Topical anesthesia of irritated oral mucous membranes and pharyngeal tissue; reduction of gagging during X-rays and dental impressions (All indications: FDA approved in infants, children, and adults); <b>Note:</b> Not approved for relief of teething pain and discomfort in infants and children; serious adverse (toxic) effects, including fatalities, have been reported (AAP 2011; AAPD 2012; ISMP 2014)</p>
<p style="text-indent:-2em;margin-left:4em;">Oral topical solution (4%): Topical anesthesia of accessible mucous membranes of the oral and nasal cavities and proximal portions of the digestive tract (FDA approved in pediatric patients [age not specified] and adults); <b>Note:</b> Not approved for relief of teething pain and discomfort in infants and children; serious adverse (toxic) effects, including fatalities, have been reported (AAP 2011; AAPD 2012; ISMP 2014)</p></div>
<div class="block mst drugH1Div" id="F54704034"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Pediatric patients: High-risk medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">KIDs List: Lidocaine viscous oral solution, when used in pediatric patients &lt;2 years of age for teething, is identified on the Key Potentially Inappropriate Drugs in Pediatrics (KIDs) list and should be avoided due to risk of seizures, arrhythmia, and death (from CNS depression, seizures, and dysrhythmias) (strong recommendation; high quality of evidence) (PPA [Meyers 2020]).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F8768676"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP1A2 (minor), CYP2A6 (minor), CYP2B6 (minor), CYP2C9 (minor), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F8768677"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Antiarrhythmic Agents (Class IB): Lidocaine (Topical) may enhance the adverse/toxic effect of Antiarrhythmic Agents (Class IB). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cimetidine: May increase the serum concentration of Lidocaine (Topical).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapsone (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Local Anesthetics: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Local Anesthetics. Specifically, the risk for methemoglobinemia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methemoglobinemia Associated Agents: May enhance the adverse/toxic effect of Local Anesthetics. Specifically, the risk for methemoglobinemia may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitric Oxide: May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Combinations of these agents may increase the likelihood of significant methemoglobinemia.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Nitrite: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Sodium Nitrite. Combinations of these agents may increase the likelihood of significant methemoglobinemia. <i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F8768629"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Lidocaine and its metabolites cross the placenta and can be detected in the fetal circulation following injection (Cavalli 2004; Mitani 1987). The amount of lidocaine absorbed topically (and therefore available systemically to potentially reach the fetus) varies by dose administered, duration of exposure, and site of application. Cumulative exposure from all routes of administration should be considered.</p></div>
<div class="block pha drugH1Div" id="F8768728"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Blocks both the initiation and conduction of nerve impulses by decreasing the neuronal membrane's permeability to sodium ions, which results in inhibition of depolarization with resultant blockade of conduction</p></div>
<div class="block phk drugH1Div" id="F14294120"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset: Intradermal injection: 1 to 3 minutes; Topical: 3 to 5 minutes; Transdermal: ~4 hours (Davies 2004)</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: Intradermal injection: 10 minutes</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Transdermal (5%): 3% ± 2% (following application of 3 patches), extent and rate variable; dependent upon concentration, dose, application site, and duration of exposure</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 60% to 80%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic via CYP1A2 (major) and CYP3A4 (minor); active metabolites monoethylglycinexylidide (MEGX) and glycinexylidide (GX)</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life, elimination: IV: 1.5 to 2 hours; prolonged 2-fold or more in hepatic impairment</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: Transdermal (5%): 11 hours (following application of 3 patches); Transdermal (1.8%): ~14 hours (following application of 3 patches)</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (&lt;10% as unchanged drug)</p></div>
<div class="block phksp drugH1Div" id="F51198327"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Accumulation of metabolites may occur.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F11390233"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Lido | Lidocaine | Procomil | Rialocaine | Versatis | Xylocaine | Xylophil | Zalocain</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Fullcaina | Gobbicaina | Indican | Lidocaina | Lidocaina Denver Farma | Lidocaina lafedar | Lidoxa | Lignocaina | Lmx | Regiocaina | Xylocaina</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Dynexan | Lidbree | Posterisan akut | Versatis | Xylocain</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Amcal skinsolve | Lignocaine | Lignocaine hydrochloride | Lmx4 | Montavit Cathejell Lignocaine | Mucosoothe | Nervoderm | Stud 100 | Versatis | Xylocaine | Xylocaine c chlor | Xylocaine c hibit | Ziagel</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Jasocaine | Leecaine | Lido | Xylogel | Xyloken | Z lidocaine</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Lonqtiv | Ophtesic | Severtos | Versatis | Xylocaine</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Procomil</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Lidbree | Lidocain | Versatis</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Cloridrato de lidocaina | Dermomax | Gel-lido | Labcaina | Lidial | Lido | Lidocaina | Lidogel | Lidojet | Lidol | Lidopass | Toperma | Xylestesin | Xylocaina</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Neurodol | Solarcaine | Xylocain</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Dimecaina | Exido | Gelcain | Lidocaina | Prolong</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Lidocaine | Lidocaine hydrochloride mucilage (i) | Xylocaine</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Farmacaina | Lidocaina | Lidocaina Hcl | Lidomax | Roxicaina | Versatis | Xylocaina</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Lidbree | Lidocain | Versatis | Xylestesin | Xylocaine</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Actilogic | Burn jel | Calmotop | Dolocupin | Dynexan | Esliva | Gelicain | Lidesthesin | Lido Posterine | Lidocain | Lidocainkreussler | Lidogalen | Lidoposterine | Lidotec | Lonioban | Posterisan akut | Sagittaproct gleitgel lidocain | Versatis | Xylocain | Xylocain pumpspray dental | Xylonor n</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Xogel | Xylocain</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Lafecaina | Lidocaina | Roxicaina | Xylestesin | Xylocaina</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Roxicaina | Versatis | Xylocaina</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Lidocain | Lidonostrum | Lignocaine | Vemcaine | Versatis | Xylocaine | Xylonor</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Dento-gel | Farco-caine | Lidocaine | Lidoged | Lidosine | Lignocaine | Lignoral | Proctolidosine | Ultracaine | Xylocaine | Xylotop</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Aeroderm | Dermovagisil | Lambdalina | Lidbree | Ophtesic | Versatis | Xilonibsa | Xylocaina</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Lidocaine</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Lidbree | Lidocain | Lidoposterin | Xylocain</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Dynexan | Dynexangival | Lidocaine Aguettant | Ophtesic | Versatis | Xylocaine</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Boots Anaesthetic Sore Throat Relief | Dequa | Lidbree | Lidocaine | Lignocaine | Lignocaine biorex | Lmx4 | Premjact | Ralvo | Strepsils | Strepsils pain relief | Stud 100 | Versatis | Xylocaine | Xylonar</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Versatis | Xylocaine | Xylojell | Xylozan</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Axcel lignocaine | Lignocaine | Lignocaine hydrochloride | Lignopad | Magicmo | Procomil | Xylocaine</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Dolokain | Lidokain | Versatis</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Lidbree | Lidocain | Versatis</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Lidonest | Xylocain | Xylocaine</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Burnjel | Lidbree | Versatis</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">After burn | Esracain | Lidocain | Xylocaine</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Caligno | Climax | Easycainne | Exygra | Gesicain | Lidfast | Lidopatch | Lidovalor | Lignocad | Lignocare | Lignox | Lox | Nummit | Oculan | Orikane | Resocaine | Stud | Wocaine | Xylocaine | Xynova | Zylo</span>;</li>
<li>
<span class="countryCode">(IQ)</span> <span class="country">Iraq</span><span class="countrySeparator">: </span><span class="drugName">Awalidocaine | Licodain | Lido rx | Lidocain | Lidocan k | Xylocaine</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Dolocopin | Dynexan | Ecocain | Elidoxil | Lidoc | Lidocaina | Lidocaina aguettant | Lidocaina formenti | Lidofast | Luan | Nydriar | Ortodermina | Truvinut | Versatis | Xilomynol | Xylocaina</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Lidover | Xylocaine | Xylophil</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Anetocaine | Anetocaine kobayashi kako | Anetocaine merck hoei | Lidocaine | Partran | Penles | Xylocaine | Youpatch</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Metacain | Xylocaine</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Acaine | Anestar | Angelcain | Anyman | Anymen | Arlico lidocaine hcl | B.m.gel | Beracaine | Beros | Bigtugel | Bluecain | Burncain | Burnen | Caeplong | Camna | Caplong | Cmg primium | Control | Cresen | Dermacan | Dipenlong | Dube | Emmao Plus | Engelcaine | Engelcaine jelly | Erex | Happycain | Hecaine | J | J cain premium | J-cain | J-ker | Jw shinyak lidocaine | Keflong | Korea pharma lidocaine | Lica l | Lidcaine | Lido m | Lidoa f | Lidoca | Lidocain jelly sungkwang | Lidocaine | Lidocan | Lidogesic cataplasma | Lidokin | Lidoplast | Liocaine f | Liocan | Lipo-max | Lmx4 | Maxcaine | Power | Powergel | Premium lido sen | Primium tag | Progelcaine | Ps | Rejucell | Riocan | Rocky gel | Rokygel | S caine | S.m.gel | Sanoba | Sc | Seracaine | Skincain | Stud | T-stone | Testokin | Thecaine | Veracaine | Wellscain | Xilonibsa | Xogel adult | Xylocaine | Yucaine | Zk ina</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Rialocaine | Versatis | Xylocaine | Zalocain</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Avocaine | Lidocain | Lmx | Versatis | Xylocaine</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Akten | Lidocain | Lidocain egis | Lidoposterin | Versatis | Xylocaine</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Dynexan | Ophtesic | Severtos | Xylocaine</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Lidocain | Versatis | Xylocaine</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Lidocaine | Xylocaine</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Betacaine | Hipoden | Lambdalina | Lidocaina | Pharmacaine | Pisacaina | Rucaina | Sensipharma | Sunicaine | Undorlan | Versatis | Xylocaina | Xylocaina d | Xylocaina m | Zk ina</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Axcel lignocaine | Gesicain | Lidocaine | Lignocaine | Lignopad | Lignoral | Locanest | Lox | Metacain | Xylocaine</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Lidocaine</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Dynexan | Instillido | Lidbree | Lidocaine vaselinecreme 3% FNA | Versatis | Xylocaine</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Acoin lidocainhydrochlorid orifarm | Posterisan akut | Versatis | Xylocain | Xylocaine</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Cathejell lignocaine | Instillagel lido | Lignocaine | Lignocaine HCL | Lmx4 | Mucosoothe | Versatis | Xylocaine plain</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Cirocaina | Lidocaina | Lidopharm | Prolong | Roxicaina | Versatis | Xilonest | Xylocaina</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Lidocaine HCL | Lignopad | Xylocaine</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Arocaine | Donligno | Lignocaine | Lignodine | Lignopharm | Ruscain | Xino | Xylocaine | Xylogel | Zyocaine</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Dynexan | Lidocain | Lidocain egis | Lidoderm | Lidogel | Lidoposterin | Lignocainum hydrochloricum | Lignox | Nanolipo | Versatis | Xylocain | Xylocaine</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Alocane | Alocane emergency burn pads | Anecream 5 | Aspercreme with lidocaine | Asperflex | Astero | Bengay tropical jasmine | Blue emu numbing pain relief | Blue tube | Burn jel | Burn Jel Plus | Burnstuff | Cidaleaze | Dermalid | Eha | Firstcare pain relief | Gen7t | Glydo | Healthwise pain relief | L.m.x. 4 plus | Lc 4 | Lc 5 | Ldo plus | Lidaflex | Lidamantle | Lido king | Lido sorb | Lidocaine | Lidocaine anorectal | Lidocaine HCL | Lidocaine Hydrochloride Jelly | Lidocanna | Lidocin | Lidocream | Lidoderm | Lidodose | Lidogel | Lidoheal 90 | Lidopac | Lidopure | Lidoreal 30 | Lidorex | Lidorxkit | Lidosense | Lidotral | Lidotrans | Lidovix l | Lidozion | Lipocaine | Lmx | Lubricaine | Lydexa | Miaderm l | Re lieved | Rectasmoothe | Recticare | Salonpas lidocaine | Sun basics burn relief | Topicaine | Tranzarel | Xylocaine | Ziloval | Zionodil | Ztlido</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Lambdalina | Lidbree | Lidocaina | Lidocaina grunenthal | Lidoject | Lidonostrum | Versatis | Vessatis | Xilonibsa | Xilotane | Xylocaina</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Curadentol | Indican | Procomil | Regiocaina | Xylestesin | Xylocaina</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Avocaine | Ledo | Lidonostrum | Lokalen | Rialocaine | Rialocaine Gel | Themicaine | Vemcaine | Versatis | Xylocaine Jelly | Xylocaine Spray | Xylocaine Topical | Zalocain</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Lidbree | Lidocain | Versatis</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Catedejel lidocain | Dinexan | Dinexan a | Dynexan | Lidocain | Lidocain vial | Lidocaine vial | Lidochlor | Luan | Versatis | Xylocaine</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Ledo | Lidocaine | Liocaine | Rialocaine | Versatis | Xylocaine | Xylocaine viscous | Xylophil | Zalocain</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Instillido | Lidbree | Maxilene | Versatis | Xylocain | Xylocain utan konserveringsmedel</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Dube | Gesicain | Lignocaine | Lignopad | Vagisil medicated cream | Xylocaine</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Cathejell lidokain | Lidocain | Versatis | Xylocain | Xylonor</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Lidbree | Lidocain | Versatis | Xylocaine</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Chalocaine | Docaine | Lido | Lignopad | Xylocaine</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Lidoca plus | Xylocaine | Xylocaine Uretral | Xylogel</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Anestol | Joymax | Ksilidin | Lidestol | Lincaine | Lmx 4 | Localen | Locanest | Lokalen | Precoxin | Redekain | Vemcaine | Xylocain</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Anebol | Donku | Lico | Lido | Lidopat | Lignocaine | Lignopad | Medisuper | Quicaine | Xylocaine</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Lidocain | Luan</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Axcel lignocaine</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Lidocaina | Lignocaina | Xylo Efa | Xylocaina</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Farmacaina | Lidocaina | Nenedent | Toperma | Xilocaina</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Remicaine | Versatis | Xylocaine | Xylotox</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Xcite</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Metacain</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-7TPharma.1">
<a name="7TPharma.1"></a>7T Lido (lidocaine) gel [prescribing information]. Los Angeles, CA: 7T Pharma LLC; October 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-topical-pediatric-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-topical-pediatric-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Quest.1">
<a name="Quest.1"></a>Alocane Emergency Burn Spray Maximum Strength (lidocaine) gel [prescribing information]. Pleasant Prairie, WI: Quest Products Inc; received September 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAPD.1">
<a name="AAPD.1"></a>American Academy of Pediatric Dentistry (AAPD). Guideline on infant oral health care. 2012. http://www.aapd.org/media/Policies_Guidelines/G_infantOralHealthCare.pdf.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.1">
<a name="AAP.1"></a>American Academy of Pediatrics Oral Health Initiative (AAP). A Pediatric Guide to Children’s Oral Health. January, 2011. http://www2.aap.org/commpeds/dochs/oralhealth/docs/OralHealthFCpagesF2_2_1.pdf.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.2">
<a name="AAP.2"></a>American Academy of Pediatrics Task Force on Circumcision. Male circumcision. <i>Pediatrics</i>. 2012;130:e756.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Solutech.1">
<a name="Solutech.1"></a>Anastia (lidocaine) [prescribing information]. Peoria, AZ: Solutech Pharmaceuticals LLC.; received September 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36162843">
<a name="36162843"></a>Antel R, Ingelmo P. Local anesthetic systemic toxicity. <i>CMAJ</i>. 2022;194(37):E1288. doi:10.1503/cmaj.220835<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-topical-pediatric-drug-information/abstract-text/36162843/pubmed" id="36162843" target="_blank">36162843</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Chattam.1">
<a name="Chattam.1"></a>Aspercreme (lidocaine) patch [prescribing information]. Chattanooga, TN: Chattam Inc; received March 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Chattam.2">
<a name="Chattam.2"></a>Aspercreme with Lidocaine Foot Pain Creme (lidocaine) [prescribing information]. Chattanooga, TN: Chattam Inc; received January 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Chattam.3">
<a name="Chattam.3"></a>Aspercreme with Lidocaine Maximum Strength Pain Relieving Creme (lidocaine) [prescribing information]. Chattanooga, TN: Chattam Inc; 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Akron.1">
<a name="Akron.1"></a>Asperflex Maximum Strength (lidocaine) [prescribing information]. Fairfield, NJ: Akron Pharma Inc; received July 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29790180">
<a name="29790180"></a>Assier H, Wolkenstein P, Chosidow O. Very late sensitization to parabens induced by repeated applications of an anaesthetic therapeutic plaster to non-damaged skin. <i>Contact Dermatitis</i>. 2018;79(3):194-195. doi:10.1111/cod.13029<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-topical-pediatric-drug-information/abstract-text/29790180/pubmed" id="29790180" target="_blank">29790180</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gensco.1">
<a name="Gensco.1"></a>Astero (lidocaine) gel [prescribing information]. Miami, FL: Gensco Laboratories LLC; June 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29525187">
<a name="29525187"></a>Bacon B, Silverton N, Katz M, et al. Local anesthetic systemic toxicity induced cardiac arrest after topicalization for transesophageal echocardiography and subsequent treatment with extracorporeal cardiopulmonary resuscitation. <i>J Cardiothorac Vasc Anesth</i>. 2019;33(1):162-165. doi:10.1053/j.jvca.2018.01.044<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-topical-pediatric-drug-information/abstract-text/29525187/pubmed" id="29525187" target="_blank">29525187</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17175824">
<a name="17175824"></a>Becker DE, Reed KL. Essentials of local anesthetic pharmacology. <i>Anesth Prog</i>. 2006;53(3):98-108; quiz 109-110. doi:10.2344/0003-3006(2006)53[98:EOLAP]2.0.CO;2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-topical-pediatric-drug-information/abstract-text/17175824/pubmed" id="17175824" target="_blank">17175824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22822998">
<a name="22822998"></a>Becker DE, Reed KL. Local anesthetics: review of pharmacological considerations. <i>Anesth Prog</i>. 2012;59(2):90-101; quiz 102-103. doi:10.2344/0003-3006-59.2.90<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-topical-pediatric-drug-information/abstract-text/22822998/pubmed" id="22822998" target="_blank">22822998</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Focus.1">
<a name="Focus.1"></a>Blue Tube (lidocaine) cream [prescribing information]. Knoxville, TN: Focus Health Group; received June 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33161140">
<a name="33161140"></a>Brites GS, Ferreira I, Sebastião AI, et al. Allergic contact dermatitis: From pathophysiology to development of new preventive strategies. <i>Pharmacol Res</i>. 2020;162:105282. doi:10.1016/j.phrs.2020.105282<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-topical-pediatric-drug-information/abstract-text/33161140/pubmed" id="33161140" target="_blank">33161140</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15365654">
<a name="15365654"></a>Cavalli Rde C, Lanchote VL, Duarte G, et al. Pharmacokinetics and Transplacental Transfer of Lidocaine and its Metabolite For Perineal Analgesic Assistance to Pregnant Women. <i>Eur J Clin Pharmacol</i>. 2004;60(8):569-574.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-topical-pediatric-drug-information/abstract-text/15365654/pubmed" id="15365654" target="_blank">15365654</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-topical-pediatric-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-topical-pediatric-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18280086">
<a name="18280086"></a>Curtis LA, Dolan TS, Seibert HE. Are one or two dangerous? Lidocaine and topical anesthetic exposures in children. <i>J Emerg Med</i>. 2009;37(1):32-39. doi:10.1016/j.jemermed.2007.11.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-topical-pediatric-drug-information/abstract-text/18280086/pubmed" id="18280086" target="_blank">18280086</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15101784">
<a name="15101784"></a>Davies PS and Galer BS. Review of lidocaine patch 5% studies in the treatment of postherpetic neuralgia. <i>Drugs</i>. 2004;64(9):937-947.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-topical-pediatric-drug-information/abstract-text/15101784/pubmed" id="15101784" target="_blank">15101784</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Llorens.1">
<a name="Llorens.1"></a>Dologesic (lidocaine) [prescribing information]. Miami, FL: Llorens Pharmaceutical International Division, Inc.; February 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10839430">
<a name="10839430"></a>Dryden RM, Lo MW. Breast milk lidocaine levels in tumescent liposuction. <i>Plast Reconstr Surg</i>. 2000;105(6):2267-2268.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-topical-pediatric-drug-information/abstract-text/10839430/pubmed" id="10839430" target="_blank">10839430</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31757230">
<a name="31757230"></a>Dykewicz MS, Lam JK. Drug hypersensitivity reactions. <i>Med Clin North Am</i>. 2020;104(1):109-128. doi:10.1016/j.mcna.2019.09.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-topical-pediatric-drug-information/abstract-text/31757230/pubmed" id="31757230" target="_blank">31757230</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Enovachem.1">
<a name="Enovachem.1"></a>Eha lotion (lidocaine) [prescribing information]. Torrance, CA: Enovachem Pharmaceuticals; received September 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12042548">
<a name="12042548"></a>Eichenfield LF, Funk A, Fallon-Friedlander S, Cunningham BB. A clinical study to evaluate the efficacy of ELA-Max (4% liposomal lidocaine) as compared with eutectic mixture of local anesthetics cream for pain reduction of venipuncture in children. <i>Pediatrics</i>. 2002;109(6):1093-1099.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-topical-pediatric-drug-information/abstract-text/12042548/pubmed" id="12042548" target="_blank">12042548</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36908108">
<a name="36908108"></a>Eisenberg J, Tedford NJ, Weaver N, Becker S, Moss MJ. Adverse outcomes in topical lidocaine exposure: A pediatric case series from the United States National Poison Data System. <i>Clin Pediatr (Phila)</i>. 2023;62(11):1390-1397. doi:10.1177/00099228231159646<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-topical-pediatric-drug-information/abstract-text/36908108/pubmed" id="36908108" target="_blank">36908108</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23109683">
<a name="23109683"></a>Fein JA, Zempsky WT, Cravero JP; Committee on Pediatric Emergency Medicine and Section on Anesthesiology and Pain Medicine; American Academy of Pediatrics. Relief of pain and anxiety in pediatric patients in emergency medical systems. <i>Pediatrics</i>. 2012;130(5):e1391-e1405.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-topical-pediatric-drug-information/abstract-text/23109683/pubmed" id="23109683" target="_blank">23109683</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29627919">
<a name="29627919"></a>Gay HC, Amaral AP. Acquired methemoglobinemia associated with topical lidocaine administration: A Case Report. <i>Drug Saf Case Rep</i>. 2018;5(1):15. doi:10.1007/s40800-018-0081-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-topical-pediatric-drug-information/abstract-text/29627919/pubmed" id="29627919" target="_blank">29627919</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7TPharma.2">
<a name="7TPharma.2"></a>Gen7T (lidocaine) lotion [prescribing information]. Las Vegas, NV: 7T Pharma LLC; received September 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7TPharma.3">
<a name="7TPharma.3"></a>Gen7T (lidocaine) patch [prescribing information]. Las Vegas, NV: 7T Pharma LLC; received September 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6883940">
<a name="6883940"></a>Giard MJ, Uden DL, Whitlock DJ, and Watson DM. Seizures induced by oral viscous lidocaine. <i>Clin Pharm</i>. 1983;2(2):110.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-topical-pediatric-drug-information/abstract-text/6883940/pubmed" id="6883940" target="_blank">6883940</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31461049">
<a name="31461049"></a>Gitman M, Fettiplace MR, Weinberg GL, Neal JM, Barrington MJ. Local anesthetic systemic toxicity: A narrative literature review and clinical update on prevention, diagnosis, and management. <i>Plast Reconstr Surg</i>. 2019;144(3):783-795. doi:10.1097/PRS.0000000000005989<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-topical-pediatric-drug-information/abstract-text/31461049/pubmed" id="31461049" target="_blank">31461049</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11321382">
<a name="11321382"></a>Giuliani M, Grossi GB, Pileri M, Lajolo C, Casparrini G. Could local anesthesia while breast-feeding be harmful to infants? <i>J Pediatr Gastroenterol Nutr</i>. 2001;32(2):142-144.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-topical-pediatric-drug-information/abstract-text/11321382/pubmed" id="11321382" target="_blank">11321382</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sagent.1">
<a name="Sagent.1"></a>Glydo (lidocaine) jelly, USP [prescribing information]. Schaumberg, IL: Sagent Pharmaceuticals; March 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7899121">
<a name="7899121"></a>Gonzalez del Rey J, Wason S, Druckenbrod RW. Lidocaine overdose: another preventable case? <i>Pediatr Emerg Care</i>. 1994;10(6):344-346.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-topical-pediatric-drug-information/abstract-text/7899121/pubmed" id="7899121" target="_blank">7899121</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8033557">
<a name="8033557"></a>Hardwick N, King CM. Contact allergy to lignocaine with cross-reaction to bupivacaine. <i>Contact Dermatitis</i>. 1994;30(4):245-246. doi:10.1111/j.1600-0536.1994.tb00657.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-topical-pediatric-drug-information/abstract-text/8033557/pubmed" id="8033557" target="_blank">8033557</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28652958">
<a name="28652958"></a>Hasan B, Asif T, Hasan M. Lidocaine-induced systemic toxicity: A case report and review of literature. <i>Cureus</i>. 2017;9(5):e1275. doi:10.7759/cureus.1275. Erratum in: <i>Cureus</i>. 2019;11(8):c24<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-topical-pediatric-drug-information/abstract-text/28652958/pubmed" id="28652958" target="_blank">28652958</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3382075">
<a name="3382075"></a>Hess GP and Walson PD. Seizures secondary to oral viscous lidocaine. <i>Ann Emerg Med</i>. 1988;17(7):725-727.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-topical-pediatric-drug-information/abstract-text/3382075/pubmed" id="3382075" target="_blank">3382075</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hotta.2022">
<a name="Hotta.2022"></a>Hotta E, Tamagawa-Mineoka R, Onishi Y, et al. Immediate hypersensitivity reaction to carboxymethylcellulose in lidocaine jelly and dimethicone drops: A case report and mini-review. <i>J Cutan Immunol Allergy</i>. 2022;5:217-221. doi:12.1002/cia2.12261</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-topical-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ISMP.1">
<a name="ISMP.1"></a>Institute for Safe Medication Practice (ISMP), “Topical anesthetics for teething infants,” ISMP Medication Safety Alert, January 14, 2014. http://www.ismp.org/newsletters/acutecare/issues/20140116.pdf.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34467556">
<a name="34467556"></a>Iolascon A, Bianchi P, Andolfo I, et al; SWG of red cell and iron of EHA and EuroBloodNet. Recommendations for diagnosis and treatment of methemoglobinemia. <i>Am J Hematol</i>. 2021;96(12):1666-1678. doi:10.1002/ajh.26340<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-topical-pediatric-drug-information/abstract-text/34467556/pubmed" id="34467556" target="_blank">34467556</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-topical-pediatric-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15601345">
<a name="15601345"></a>Koh JL, Harrison D, Myers R, Dembinski R, Turner H, McGraw T. A randomized, double-blind comparison study of EMAL and ELA-Max for topical anesthesia in children undergoing intravenous insertion. <i>Paediatr Anesth</i>. 2004;14(12):977-982.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-topical-pediatric-drug-information/abstract-text/15601345/pubmed" id="15601345" target="_blank">15601345</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gensco.1">
<a name="Gensco.1"></a>LDO Plus (lidocaine) gel [prescribing information]. Miami, FL: Gensco Laboratories LLC; October 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8408724">
<a name="8408724"></a>Lebedevs TH, Wojnar-Horton RE, Yapp P, et al. Excretion of Lignocaine and its Metabolite Monoethylglycinexylidide in Breast Milk Following its Use in a Dental Procedure. A Case Report. <i>J Clin Periodontol</i>. 1993;20(8):606-608.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-topical-pediatric-drug-information/abstract-text/8408724/pubmed" id="8408724" target="_blank">8408724</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16041631">
<a name="16041631"></a>Lehr VT, Cepeda E, Frattarelli DA, et al, "Lidocaine 4% Cream Compared With Lidocaine 2.5% and Prilocaine 2.5% or Dorsal Penile Block for Circumcision," <i>Am J Perinatol</i>, 2005, 22(5):231-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-topical-pediatric-drug-information/abstract-text/16041631/pubmed" id="16041631" target="_blank">16041631</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sola.1">
<a name="Sola.1"></a>LidaFlex (lidocaine) [prescribing information]. Baton Rouge, LA: Sola Pharmaceuticals LLC; received February 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HiTech.1">
<a name="HiTech.1"></a>Lidocaine 3.5% patch [prescribing information]. Las Vegas, NV: 7T Pharma, LLC; received August 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HiTech.1">
<a name="HiTech.1"></a>Lidocaine 5% ointment [prescribing information]. Amityville, NY: Hi-Tech Pharmacal Co Inc; February 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AUM.1">
<a name="AUM.1"></a>Lidocaine 4% ointment [prescribing information]. Hauppauge, NY: AUM Pharmaceuticals; received February 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Alvix.1">
<a name="Alvix.1"></a>Lidocaine hydrochloride 3% lotion [prescribing information]. Ocean Springs, MS: Alvix Laboratories; February 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-PharmaPure.1">
<a name="PharmaPure.1"></a>Lidocaine hydrochloride 4.12% cream [prescribing information]. San Fernando, CA: PharmaPure RX; April 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-QualityCare.1">
<a name="QualityCare.1"></a>Lidocaine hydrochloride gel [prescribing information]. Holland, OH: Quality Care Products, LLC; December 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WestWard.1">
<a name="WestWard.1"></a>Lidocaine hydrochloride solution [prescribing information]. Eatontown, NJ: West-Ward Pharmaceuticals Corp; August 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Teligent.1">
<a name="Teligent.1"></a>Lidocaine hydrochloride topical solution [prescribing information]. Buena, NJ: Teligent Pharma Inc; February 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Burke.1">
<a name="Burke.1"></a>Lidocaine suppository (lidocaine) [prescribing information]. Hot Springs, AR: Burke Therapies LLC; January 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lannett.1">
<a name="Lannett.1"></a>Lidocaine Viscous 2% (lidocaine) [prescribing information]. Carmel, NY: Lannett Company, Inc; February 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lannett.1">
<a name="Lannett.1"></a>Lidocan Patch 5% (lidocaine) [prescribing information]. Panorama City, CA; PureTek Corp; received July 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Endo.1">
<a name="Endo.1"></a>Lidoderm (lidocaine patch 5%) [prescribing information]. Malvern, PA: Endo Pharmaceuticals; November 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gensco.2">
<a name="Gensco.2"></a>LidoDose (lidocaine hydrochloride 3%) topical anesthetic, single-use applicator [prescribing information]. Miami, FL: Gensco Pharma; April 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Solutech.1">
<a name="Solutech.1"></a>Lido-K (lidocaine) [prescribing information]. Peoria, AZ: Solutech Pharmaceuticals; February 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-JARLab.1">
<a name="JARLab.1"></a>Lidopatch (lidocaine) [prescribing information]. Lake Forest, IL: JAR Laboratories; November 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gensco.2">
<a name="Gensco.2"></a>LiDORx (lidocaine) gel [prescribing information]. Miami, FL: Gensco Pharma LLC; November 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cloverleaf.1">
<a name="Cloverleaf.1"></a>Lido-Rx 4.1 (lidocaine) [prescribing information]. Pensacola, FL: Cloverleaf Pharma LLC; January 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-PureTek.1">
<a name="PureTek.1"></a>Lidotran (lidocaine cream 3.88%) [prescribing information]. Panorama City, CA: PureTek Corporation; March 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sterling.1">
<a name="Sterling.1"></a>Lidotrex (lidocaine) gel [prescribing information]. Ripley, MS: Sterling-Knight Pharmaceuticals LLC; March 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sterling.2">
<a name="Sterling.2"></a>Lidovex (lidocaine cream 3.75%) [prescribing information]. Ripley, MS: Sterling-Knight Pharmaceuticals; December 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sterling.3">
<a name="Sterling.3"></a>Lidovex (lidocaine cream) [prescribing information]. Ripley, MS: Sterling-Knight Pharmaceuticals LLC; January 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ESBA.1">
<a name="ESBA.1"></a>Lipocaine 5 (lidocaine) cream [prescribing information]. Jupiter, FL: ESBA Laboratories Inc; received March 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ferndale.1">
<a name="Ferndale.1"></a>LMX4 cream (lidocaine) [prescribing information]. Ferndale, MI: Ferndale Laboratories, Inc; June 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ferndale.2">
<a name="Ferndale.2"></a>LMX5 cream (lidocaine) [prescribing information]. Ferndale, MI: Ferndale Laboratories, Inc; June 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10515104">
<a name="10515104"></a>Lodi A, Ambonati M, Coassini A, Kouhdari Z, Palvarini M, Crosti C. Contact allergy to 'caines' caused by anti-hemorrhoidal ointments. <i>Contact Dermatitis</i>. 1999;41(4):221-222. doi:10.1111/j.1600-0536.1999.tb06136.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-topical-pediatric-drug-information/abstract-text/10515104/pubmed" id="10515104" target="_blank">10515104</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35777259">
<a name="35777259"></a>Long B, Chavez S, Gottlieb M, Montrief T, Brady WJ. Local anesthetic systemic toxicity: A narrative review for emergency clinicians. <i>Am J Emerg Med</i>. 2022;59:42-48. doi:10.1016/j.ajem.2022.06.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-topical-pediatric-drug-information/abstract-text/35777259/pubmed" id="35777259" target="_blank">35777259</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ESBA.2">
<a name="ESBA.2"></a>Lubricaine Anorectal (lidocaine) gel [prescribing information]. Jupiter, FL: ESBA Labs Inc; received March 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ESBA.3">
<a name="ESBA.3"></a>Lubricaine for Her (lidocaine) gel [prescribing information]. Jupiter, FL: ESBA Labs Inc; received March 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14993579">
<a name="14993579"></a>Luhmann J, Hurt S, Shootman M, Kennedy R. A comparison of buffered lidocaine versus ELA-Max before peripheral intravenous catheter insertions in children. <i>Pediatrics</i>. 2004;133(3 pt 1):e217-e220.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-topical-pediatric-drug-information/abstract-text/14993579/pubmed" id="14993579" target="_blank">14993579</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-topical-pediatric-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12622627">
<a name="12622627"></a>Mackley CL, Marks JG Jr, Anderson BE. Delayed-type hypersensitivity to lidocaine. <i>Arch Dermatol</i>. 2003;139(3):343-346. doi:10.1001/archderm.139.3.343<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-topical-pediatric-drug-information/abstract-text/12622627/pubmed" id="12622627" target="_blank">12622627</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16924052">
<a name="16924052"></a>Marra DE, Yip D, Fincher EF, Moy RL. Systemic toxicity from topically applied lidocaine in conjunction with fractional photothermolysis. <i>Arch Dermatol</i>. 2006;142(8):1024-1026. doi:10.1001/archderm.142.8.1024<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-topical-pediatric-drug-information/abstract-text/16924052/pubmed" id="16924052" target="_blank">16924052</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32265601">
<a name="32265601"></a>Meyers RS, Thackray J, Matson KL, et al. <i>K</i>ey Potentially <i>I</i>nappropriate <i>D</i>rugs in Pediatrics: The KIDs List. <i>J Pediatr Pharmacol Ther</i>. 2020;25(3):175-191.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-topical-pediatric-drug-information/abstract-text/32265601/pubmed" id="32265601" target="_blank">32265601</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3297463">
<a name="3297463"></a>Mitani GM, Steinberg I, Lien EJ, et al. The Pharmacokinetics of Antiarrhythmic Agents in Pregnancy and Lactation. <i>Clin Pharmacokinet</i>. 1987;12(4):253-291.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-topical-pediatric-drug-information/abstract-text/3297463/pubmed" id="3297463" target="_blank">3297463</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6825363">
<a name="6825363"></a>Mofenson HC, Caraccio TR, Miller H, Greensher J. Lidocaine toxicity from topical mucosal application. With a review of the clinical pharmacology of lidocaine. <i>Clin Pediatr (Phila)</i>. 1983;22(3):190-192.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-topical-pediatric-drug-information/abstract-text/6825363/pubmed" id="6825363" target="_blank">6825363</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29671489">
<a name="29671489"></a>Montanez-Wiscovich ME, Ogbonna NJ. Geometric rash on the leg. <i>Am Fam Physician</i>. 2018;97(8):531-532.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-topical-pediatric-drug-information/abstract-text/29671489/pubmed" id="29671489" target="_blank">29671489</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29356773">
<a name="29356773"></a>Neal JM, Barrington MJ, Fettiplace MR, et al. The Third American Society of Regional Anesthesia and Pain Medicine Practice Advisory on Local Anesthetic Systemic Toxicity: Executive Summary 2017. <i>Reg Anesth Pain Med</i>. 2018;43(2):113-123. doi:10.1097/AAP.0000000000000720<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-topical-pediatric-drug-information/abstract-text/29356773/pubmed" id="29356773" target="_blank">29356773</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10225071">
<a name="10225071"></a>Ortega D, Viviand X, Lorec AM, et al. Excretion of Lidocaine and Bupivacaine in Breast Milk Following Epidural Anesthesia for Cesarean Delivery. <i>Acta Anaesthesiol Scand</i>. 1999;43(4):394-397.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-topical-pediatric-drug-information/abstract-text/10225071/pubmed" id="10225071" target="_blank">10225071</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4051869">
<a name="4051869"></a>Puczynski MS, Ow EP, and Rust C. Cardiopulmonary arrest due to misuse of viscous lidocaine. <i>Arch Otolaryngol</i>. 1985;111(11):768-769.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-topical-pediatric-drug-information/abstract-text/4051869/pubmed" id="4051869" target="_blank">4051869</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30009240">
<a name="30009240"></a>Rahimi M, Elmi M, Hassanian-Moghaddam H, et al. Acute lidocaine toxicity; a case series. <i>Emerg (Tehran)</i>. 2018;6(1):e38.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-topical-pediatric-drug-information/abstract-text/30009240/pubmed" id="30009240" target="_blank">30009240</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7108671">
<a name="7108671"></a>Rothstein P, Dornbusch J, Shaywitz BA. Prolonged seizures associated with the use of viscous lidocaine. <i>J Pediatr</i>. 101(3):461-463.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-topical-pediatric-drug-information/abstract-text/7108671/pubmed" id="7108671" target="_blank">7108671</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3113575">
<a name="3113575"></a>Ruffles SP, Gayres JG. Fatal bronchospasm after topical lignocaine before bronchoscopy. <i>Br Med J (Clin Res Ed)</i>. 1987;294(6588):1658-1659. doi:10.1136/bmj.294.6588.1658-a<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-topical-pediatric-drug-information/abstract-text/3113575/pubmed" id="3113575" target="_blank">3113575</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7361745">
<a name="7361745"></a>Sakai RI, Lattin JE. Lidocaine ingestion. <i>Am J Dis Child</i>. 1980;1344(3):323.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-topical-pediatric-drug-information/abstract-text/7361745/pubmed" id="7361745" target="_blank">7361745</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19188870">
<a name="19188870"></a>Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-topical-pediatric-drug-information/abstract-text/19188870/pubmed" id="19188870" target="_blank">19188870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-topical-pediatric-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1401862">
<a name="1401862"></a>Smith M, Wolfram W, Rose R. Toxicity- seizures in an infant caused by (or related to) oral viscous lidocaine use. <i>J Emerg Med</i>. 1992;10(5):587-590.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-topical-pediatric-drug-information/abstract-text/1401862/pubmed" id="1401862" target="_blank">1401862</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22243434">
<a name="22243434"></a>Sobanko JF, Miller CJ, Alster TS. Topical anesthetics for dermatologic procedures: a review.<i> Dermatol Surg</i>. 2012;38(5):709-721.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-topical-pediatric-drug-information/abstract-text/22243434/pubmed" id="22243434" target="_blank">22243434</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hisamitsu.1">
<a name="Hisamitsu.1"></a>Solanpas (lidocaine) gel [prescribing information]. Florham Park, NJ: Hisamitsu America Inc; received May 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15967972">
<a name="15967972"></a>Taddio A, Soin HK, Schuh S, Koren G, Scolnik D. Liposomal lidocaine to improve procedural success rates and reduce procedural pain among children: a randomized controlled trial. <i>CMAJ</i>. 2005;172(13):1691-1695.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-topical-pediatric-drug-information/abstract-text/15967972/pubmed" id="15967972" target="_blank">15967972</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25380091">
<a name="25380091"></a>To D, Kossintseva I, de Gannes G. Lidocaine contact allergy is becoming more prevalent. <i>Dermatol Surg</i>. 2014;40(12):1367-1372. doi:10.1097/DSS.0000000000000190<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-topical-pediatric-drug-information/abstract-text/25380091/pubmed" id="25380091" target="_blank">25380091</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ESBA.3">
<a name="ESBA.3"></a>Topicaine 4 (lidocaine) gel [prescribing information]. Jupiter, FL: ESBA Laboratories Inc; January 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ESBA.4">
<a name="ESBA.4"></a>Topicaine 5 (lidocaine) gel [prescribing information]. Jupiter, FL: ESBA Laboratories Inc; received March 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37283623">
<a name="37283623"></a>Tramontana M, Hansel K, Bianchi L, Sensini C, Malatesta N, Stingeni L. Advancing the understanding of allergic contact dermatitis: from pathophysiology to novel therapeutic approaches. <i>Front Med (Lausanne)</i>. 2023;10:1184289. doi:10.3389/fmed.2023.1184289<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-topical-pediatric-drug-information/abstract-text/37283623/pubmed" id="37283623" target="_blank">37283623</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Taleos.1">
<a name="Taleos.1"></a>Tranzarel (lidocaine) [prescribing information]. Eatontown, NJ: Taleos Pharma Corp.; August 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20831930">
<a name="20831930"></a>Trapp L, Will J. Acquired methemoglobinemia revisited. <i>Dent Clin North Am</i>. 2010;54(4):665-675. doi:10.1016/j.cden.2010.06.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-topical-pediatric-drug-information/abstract-text/20831930/pubmed" id="20831930" target="_blank">20831930</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31932460">
<a name="31932460"></a>Walters E, Wurster Ovalle V, Yin S, Dribin T. Infant with status epilepticus secondary to systemic lidocaine toxicity from topical application. <i>BMJ Case Rep</i>. 2020;13(1):e233119. doi:10.1136/bcr-2019-233119 Corrected and republished in: <i>Drug Ther Bull</i>. 2020;58(9):141-143.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-topical-pediatric-drug-information/abstract-text/31932460/pubmed" id="31932460" target="_blank">31932460</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9840272">
<a name="9840272"></a>Weightman W, Turner T. Allergic contact dermatitis from lignocaine: report of 29 cases and review of the literature. <i>Contact Dermatitis</i>. 1998;39(5):265-266. doi:10.1111/j.1600-0536.1998.tb05928.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-topical-pediatric-drug-information/abstract-text/9840272/pubmed" id="9840272" target="_blank">9840272</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22568708">
<a name="22568708"></a>Weingarten TN, Gleich SJ, Craig JR Jr, Sprung J. Methemoglobinemia in the setting of chronic transdermal lidocaine patch use. <i>Pain Med</i>. 2012;13(7):976-977. doi:10.1111/j.1526-4637.2012.01383.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-topical-pediatric-drug-information/abstract-text/22568708/pubmed" id="22568708" target="_blank">22568708</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Akorn.1">
<a name="Akorn.1"></a>Xylocaine 2% jelly (lidocaine hydrochloride) [prescribing information]. Lake Forest, IL: Akorn, Inc.; June 2012.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aspen.1">
<a name="Aspen.1"></a>Xylocaine Endotracheal (lidocaine non-aerosol spray) [package insert]. Toronto, Ontario, Canada; Aspen Pharmacare Canada Inc: March 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3757781">
<a name="3757781"></a>Zeisler JA, Gaarder TD, De Mesquita SA. Lidocaine excretion in breast milk. <i>Drug Intell Clin Pharm</i>. 1986;20(9):691-693.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-topical-pediatric-drug-information/abstract-text/3757781/pubmed" id="3757781" target="_blank">3757781</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7TPharma.4">
<a name="7TPharma.4"></a>Zingo (lidocaine) [prescribing information]. Las Vegas, NV: 7T Pharma LLC; November 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bodysphere.1">
<a name="Bodysphere.1"></a>Zionodil (lidocaine) [prescribing information]. Las Vegas, NV: Bodysphere, LLC; received December 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Scilex.1">
<a name="Scilex.1"></a>ZTlido (lidocaine) [prescribing information]. Palo Alto, CA: Scilex Pharmaceuticals Inc; April 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Whitestone.1">
<a name="Whitestone.1"></a>Zylotrol-L (lidocaine) [prescribing information]. Sacramento, CA: Whitestone Products LLC; received January 2022.</div>
</li></ol></div><div id="topicVersionRevision">Topic 16015 Version 889.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
